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PREFACE
The purpose of this paper is to contribute to the discussion and
evaluation of some new and emerging technologies of genetic medicine.
The focus is upon the growing acquisition of new diagnostic capabilities,
their consequent impact on screening and counseling for genetic disease,
and the policy issues stemming from these capabilities.
It is becoming commonplace that modern technologies affect society
in important and complex ways. They affect both our physical and
psychic health and pervade our cultural and value systems, raising
questions about the proper goals of society and about the proper means
for pursuing those goals. They have an inescapable impact upon human
life-styles, upon relationships between men, and upon man's understanding
of himself. By its very nature technology promotes or retards what
man considers valuable.
Such is the case with genetic technology. But this technology
is unique: rather than merely acting upon man's environment, it operates
directly on man himself. New genetic technology holds great promise
for conquering disease and relieving human suffering. It is also
providing man with the ability to unlock the most fundamental of life's
processes, thus giving him the power to modify and perhaps control the
quality and capacities of his species. Moreover, such actions may be
irreversible. Genetic technology raises profound and complex questions
for society and its policy-making processes: Who shall benefit from and
iv
who shall pay for the use of this new technology? What are its
probable effects on societal values and the distribution of political
power? How will it affect our social and legal institutions? And
on what basis will society allocate decisions to either personal
conscience or public policy?
The new options created by genetic technology also raise profound
questions about the appropriate priorities of our society. Faced with
finite constraints on both money and manpower, decisions will have to
be made regarding the support, use and control of genetic technology.
These decisions are best made within the broader context of overall
national goals, i.e: should a greater public investment be made in health
or in military security?, as well as within the more limited scope
of our health goals, i.e. should society continue to invest in more
genetics research or should greater emphasis be given to distributing
medical care on a more equitable basis? In addition, this new technology
will increase the tensions between societal and individual values.
Some just relationship between these values must be established in order
to ensure the good of society while simultaneously protecting the
rights of the individual. In each case, to choose one alternative or
the other (or not to choose at all) implies an acceptance of certain
uses of technology and not of others. Such choices are inherent in
any social or political system and they are not neutral choices. They
involve conscious judgments about what society considers valuable.
Conscious efforts to determine the desirability of a particular
technology require a basic understanding of technological capability.
This paper begins, therefore, with a "state-of-the-art" review which
Vis designed to provide a general and non-technical overview of current
technological capability and the direction in which it is moving. The
paper then explores some of the issues raised by the application
of genetic technology. During the past several years, the mass
media has given a good deal of emphasis to the more sensational
applications of biomedical research, such as the creation of "test
tube babies" and "genetic engineering." l Such promethean predictions
have raised both hopes and fears among the public. While it is not
the purpose of this paper to discuss the merits of such reporting,
a major premise is that the sharpest challenges to our policy-making
capability posed by genetic technology are already in view and pose
more immediate policy concerns than do the more dramatic possibilities.
The issues are indeed complex and the uncertainty which pervades
them makes it clear that one needs to proceed cautiously in attempting
to resolve them. Yet while the solutions and guidelines will take
longer to construct, their propriety and efficacy will depend largely
upon our ability to ask the proper questions and to identify the
important issues. It is to these purposes that this paper is primarily
directed.
The preparation of this paper was made easier because of the
generous help of many people. Dr. Louis H. Mayo, Professor of Law and
Director of the Program of Policy Studies in Science and Technology,
1For example, a Durham Sun headline read, "Through Genetic
Manipulation - Superhuman Race Said Possibility," April 8, 1967,
p. 3; and a widely-read cover story of Time was titled, "The New
Genetics: Man into Superman," April 19, T1971.
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provided the initial idea and encouragement for the paper. John M.
Logsdon, Director of George Washington University's Graduate Program in
Science, Technology and Public Policy created a friendly environment
in which I could work and provided helpful comments regarding a
preliminary draft of the manuscript. Others who read earlier versions
of the manuscript and whose comments were very helpful in preparing
the final paper include John Fletcher, Cecil B. Jacobson and James R.
Sorenson. I am also grateful to Dr. Jacobson for the opportunity to
attend some of his genetic counseling sessions. My thanks also go to
Robert Ehrhardt, Pat Faber and Martha Tappe and to Marcia Smith, whose
patience and perseverance were instrumental in translating my thoughts
onto paper. The preparation of this paper was partially supported by
NSF Grant GS-34902. Of course, responsibility for the paper's content
is solely mine.
In his study The Meaning of the Twentieth Century, Kenneth
Boulding suggested that today we are "at the edge of a biological
revolution, which may have results for mankind just as dramatic as the
2
nuclear revolution of a generation ago." While the nuclear age
brought us powerful tools for benefiting mankind, it also brought
overwhelming destruction and continues to generate feelings of fear and
anxiety. Genetic technology offers a similar dilemma. Any attempt to
resolve this dilemma in a consistent and humane manner will require a
sober and anticipatory look at this "biological revolution."
M. S. F.
March, 1973
2
(Harper and Row: New York, 1964), p. 7.
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INTRODUCTION
Recent discoveries in medical genetics are permitting greater intervention
into and manipulation of the genetic endowment of man. What was once accepted
as a matter of fate is now becoming more susceptible to control by man. The
rapid growth of various genetic technologies is providing an improved capability
to diagnose, treat and eliminate numerous individual genetic qualities.
The improved capability to detect genetic defects in an unborn child now
permits parents, in the case of some genetic diseases, to know if their child
will be afflicted. If a genetic defect is diagnosed early enough in the
pregnancy, parents can choose to terminate the pregnancy. On a much broader
level, the ability to identify carriers of genetic defects by quick and simple
medical tests permits large segments of the population to be screened and
increases the potential for better control of genetic disease. Thus, couples
who have not yet had their first child can learn whether they are at risk and,
if they decide to conceive, can know whether their child is affected.
While this growing technological capability promises significant
improvements in genetically-based health, it also raises complex questions
regarding its application. For example, what defects are of such gravity as
to justify intervention? What level of confidence in diagnostic capability
is acceptable for making and implementing policy decisions? Should screening
programs be voluntary or made compulsory? And by what criteria and by whom are
these decisions to be made? Answers to these questions will be strongly
influenced by and eventually reflect the interaction of prevailing values with
increasing technological capability.
2GENETIC DISEASE: NATURE AND SCOPE
At least 1800 human diseases have been linked to a genetic cause ; new
examples are being added to this list every year. In the United States, it
is estimated that one of every 250 babies has a genetic defect which will result
in mental retardation or physical disability2 and that "at least 25 per cent
of hospital beds and of all institutional places for the handicapped in this
country are occupied by persons suffering some degree of genetic disease."3
In addition to these affected persons, approximately 25 per cent of all
conceptions are aborted naturally, and most of these can be related to an
abnormal chromosome constitution or a lethal genotype.4
There are four types of genetic disease. The first of these includes
single-gene disorders that may be either transmitted from one parent or both
or might result from a new mutation. These diseases can be dominant, in which
one of the parents is affected and each child has a 50 per cent chance of being
affected (e.g. Huntington's chorea); recessive, in which both parents are normal
1Victor A. McKusick, Mendelian Inheritance in Man, (The Johns Hopkins
University Press: Baltimore, 1971). This figure includes those diseases for
which the evidence for the particular mode of inheritance is judged to be
incomplete, yet sufficiently strong to warrant inclusion.
2The NIH Record, Vol. 24, July 18, 1972, p. 8.
3Joshua Lederberg, Testimony on the 1971 Budget Appropriations for the
Departments of Labor and Health, Education and Welfare, House Appropriations
Subcommittee Hearings, 91st Congress, 2nd Session, Part 7, 1971, p. 915.
4Working Committee on Church and Society, "Three Reports From Church and
Society," Study Encounter, Vol. 7, 1971 (World Council of Churches: Geneva),
p. 5.
3and each child has a 25 per cent chance of being affected, with 50 per cent of
the children being heterozygous5 and 25 per cent being homozygous6 for the
normal gene (e.g. sickle-cell anemia); or sex-linked,7 in which a gene that
produces a certain phenotypic trait is located on the X-chromosome (e.g.
hemophilia). All genetically determined diseases related to an enzyme
deficiency8 are inherited by recessive or sex-linked mechanisms. A mutation
involves a change in the genetic material which results in a new inherited
variant. Most mutations are eliminated because they kill the cells in which
they arise or their effects are countered by a preponderence of normal cells.
Of those mutations that do surface in the individual, some are useful in
helping him to adapt to his environment; the majority, however, are harmful
and sometimes lethal to the individual in whom they are expressed.
The second type of genetic disease is exemplified by aberrations in the
number and structure of chromosomes (e.g. Down's syndrome). In these instances,
the abnormality is generally not transmitted, but is a result of a de novo
event in the germ cells of the parents or in the initial division of the
fertilized egg. It has been calculated that each year in the United States
5An individual inheriting different genes from two parents is said to
be heterozygous.
6An individual who inherits the same gene, defective or otherwise, from
both parents is said to be homozygous.
7The 46 chromosomes of the human complement consist of 22 homologous pairs
of autosomal chromosomes and a pair of sex chromosomes. The sex chromosomes
are designated X and Y, the female having an XX constitution and the male one
X chromosome and one Y chromosome.
8Victor A. McKusick has identified 92 disorders which are related to a
specific enzyme. See "Human Genetics," Annual Review of Genetics, Vol. 4,
1970, pp. 9-11.
4approximately 20,000 infants are born with a chromosome abnormality.9
Another category of genetic disease includes those caused by the
interaction of multiple genes (e.g. diabetes). In these disorders, knowledge
about the number of genes involved and how they interact is very limited. Yet
the greatest proportion of those suffering from genetic disease are people
with multigenic variety.
Finally, the fourth type of genetic disease is caused by incompatibility
between fetus and mother, such as Rh hemolytic disease of the newborn.
When considered as a group, genetic disorders make up a highly visible
and growing problem, resulting in significant individual and social burdens.
Society's ability to cope with the illness which characterizes these diseases
is, to a great extent, due to its increasing technological capability.
What follows is a look at some of the more important techniques for the
detection, treatment and prevention of genetic disease.
GENETIC TECHNOLOGY: STATE-OF-THE-ART
I. Intrauterine Diagnosis
The goal of intrauterine diagnosis is the detection of possible fetal
abnormality in time to prevent its occurrence or to prevent disability from the
initial defect by early treatment. There has been rapid progress in developing
such techniques and while the number of disorders that can be diagnosed in
utero is still relatively small, it is likely that the list will grow rapidly
9H. A. Luks and F. H. Ruddle, ,Chromosomal Abnormalities in the Human
Population: Estimation of Rates Based on New Haven Newborn Study," Science,
Vol. 169, July 31, 1970, p. 497.
5as new and more sophisticated technologies are developed. Among the existing
technologies are:
A. Amniocentesis: Abdominal amniocentesis involves the removal of
approximately 10-20 ml. of fluid from the amniotic cavity by a syringe.
Reliable cytogenetic and biochemical techniques have been developed to evaluate
the intrauterine status of the fetus and some 40-50 genetic diseases can now
10
be diagnosed by this method. The cells are cultured and an individual's
karyotype (his particular chromosome complement) is determined. The absence,
duplication, or positional rearrangement of certain morphological features
of the chromosomes, as compared with their typical topography, is visible
evidence of chromosome mutation. In addition, the diagnosis of many inborn
errors of metabolism is possible, based on demonstrating an abnormal level
of enzyme activity in the cultured cells. It is likely that the increased
availability and automation of assay procedures, including chromosome analysis,
will expand the use of amniocentesis in the future. 11
There are other considerations, however, which must be included in any
assessment of this procedure. For instance, the most desirable time to
perform amniocentesis - both in terms of the number of cells available for
culture and of the minimal amount of risk to both the fetus and mother - is
10Aubrey Milunsky, John W. Littlefield, Julian N. Kanfer, Edwin H.
Kolodny, Vivian E. Shih and Leonard Atkins, "Prenatal Genetic Diagnosis,"
The New England Journal of Medicine, 283: 1370-1381, December 17, 1970.
11Theodore Friedmann, "Prenatal Diagnosis of Genetic Disease," Scientific
American, Vol. 225, November 1971, p. 36; Also, Joan Lynn Arehart, "Prenatal
Diagnosis: How Fast, How Far?," Science News, 100:44-45, July 17, 1971.
between the 17th and 20th post-menstrual week of the pregnancy.12 Since the
length of time required to acquire sufficient cells for biochemical analysis
13
is four to six weeks, the pregnancy will be in its 20-22nd week before a
final diagnosis is made. If a therapeutic abortion is to follow, the long
culture time raises several problems. Twenty to twenty-two weeks is past the
time when most physicians would ideally prefer to perform an abortion.
Furthermore, psychological and emotional problems (infra, p. 62) become
more intense as the period of waiting increases.
There is also the problem of distinguishing between the affected homozygote
and the heterozygote carrier. In the Lesch-Nyhan syndrome, a sex-linked
disease characterized by mental retardation for which there is no treatment,
the heterozygote and homozygote can be distinguished through prenatal
diagnosis.14 However, for most genetic disorders such a determination cannot
be made.15 When deciding whether or not to abort a fetus this technical
problem raises important questions regarding genetic screening and counseling.
12Interview with Cecil B. Jacobson, Chief of the Reproductive Genetics
Unit, George Washington University Clinic, Washington, D.C., September 19,
1972. For a discussion of the problems involved in obtaining reliable cultures
and minimizing the risk to both the fetus and mother, see Niels Hahnemann,
"Possibility of Culturing Foetal Cells at Early States of Pregnancy," Clinical
Genetics, 3: 286-93, 1972.
13M. M. Nelson and A. E. H. Emery, "Amniotic Fluid Cells: Prenatal Sex
Prediction and Culture," British Medical Journal, Vol. 1, Feb. 28, 1970, p. 525.
J. A. Boyle, K. 0. Raivo, K. H. Astrin, J. D. Schulman, M. L. Graf,
J. E. Seegmiller, and C. B. Jacobson, "Lesch-Nyhan Syndrome: Preventive
Control by Prenatal Diagnosis," Science, Vol. 169, August 14, 1970, p. 688.
15Leonard Reisman and Adam Matheny, Genetics and Counseling in Medical
Practice, (The C. V. Mosby Co.: St. Louis, 1969), p. 71.
7Finally, one must also consider the risks involved. When amniocentesis
is performed early (between 16-20 weeks) in pregnancy, the risks to the
mother include bleeding, infection and blood group sensitization; those to
the fetus include spontaneous abortion, fetal puncture and induced
malformations.16 Recent studies indicate that the occurrence of such risks
during the second trimester of pregnancy is "less than 1 per cent."17 At this
18
time, however, very little is known about the long-term risks to the fetus.
B. Ultrasound: High frequency sound is another method of prenatal
diagnosis, with the sound either transmitted through a transducer or pictured
on an oscilloscope screen. The advantage of this technique is that "all body
tissues, except bone and air-filled lungs are relatively permeable to
ultrasonic energy . . . This permits visualization, noninvasively, and with
adequate resolution, of even the deepest structures in the body with ultrasound
16
Henry Nadler and Albert Gerbie, "Present Status of Amniocentesis
in Intrauterine Diagnosis of Genetic Defects," Obstetrics and Gynecology,
Vol. 38, November 1971, p. 794.
17Henry Nadler and Albert Gerbie, "Role of Amniocentesis in the
Intrauterine Detection of Genetic Disorders," The New England Journal of
Medicine, Vol. 282, March 12, 1970, p. 599. In what may be the longest
on-going study of the risks involved in amniotic taps, Cecil B. Jacobson of
The George Washington University reports that he has performed 580 taps with
100 per cent diagnostic accuracy. Only two pregnancies have been lost and
both were confirmed as being independent of the amniotic tap. Paper presented
at the American Association for the Advancement of Science annual meeting,
Washington, D.C., December 28, 1972.
18In order to assess possible long-term risks, the National Institute
of Child Health and Human Development of the National Institutes of Health
is conducting an investigation in which patients not undergoing amniocentesis
will be studied in parallel with those undergoing the procedure.
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at sufficiently low intensity levels." Moreover, the normal ultrasonic
appearance of many fetal organs has been identified, making abnormalities of
those organs susceptible to detection.20 As a complement to amniocentesis,
ultrasound can be used to determine the exact position of the placenta, which
will permit greater accuracy and lessen the risk in withdrawing amniotic
fluid.21 A situation might also arise when diagnosis involves the presence
of twins. The reliability of evaluation with amniocentesis in multiple
pregnancies, however, is somewhat uncertain.22 Ultrasound can be useful in
these instances and, in fact, one study has reported a 99.75 per cent level
of accuracy in diagnosing multiple pregnancies.23
The use of ultrasound is limited to some extent by the high cost of
equipment and the scarcity of physicians trained to interpret the results.
With respect to potential risks, a recent study has found some hazard with
the application of this technique.24 However, other investigators have been
unable to reproduce these results even with longer exposure and higher
19Padmakar P. Lele, "Application of Ultrasound in Medicine," The New
England Journal of Medicine, Vol. 286, June 15, 1972, p. 1317.
20George Kossoff and William J. Garrett, "Ultrasonic Film Echography
in Gynecology and Obstetrics," Obstetrics and Gynecology, Vol. 40, September
1970, p. 305.
Joan Lynn Arehart, "Sounding Out the Womb," Science News, Vol. 100,
December 25, 1971, p. 424.
22Nadler and Gerbie, op. cit., supra, n. 16 at 795.
23Ross E. Brown, "Doppler Ultrasound in Obstetrics," The Journal of the
American Medical Association, Vol. 218, November 29, 1971, p. 1399.
I. J. C. Macintosh and D. A. Davey, "Chromosome Aberrations Induced
by an Ultrasonic Fetal Pulse Detected," British Medical Journal,4:92-93,
October 10, 1970. The investigators found evidence that chromosomal
aberrations were induced in human lymphocytes following exposure to ultrasound.
They employe5 intensities in the conventional Doppler diagnostic region
(10-20 mWcm- ).
9intensities.25 The evidence seems to indicate that there is little risk
associated with ultrasound, with a recent investigation concluding that "from
all the evidence available, both experimental and clinical, it is conceded
that the current diagnostic practices pose no short-term or long-term hazard
26
to the patient or to the fetus."
C. Fluorescent Staining: Whereas the usual karyotype exhibits only a
silhouette of chromosomes, fluorescent analysis reveals numerous chromosome
details. By using the chemical agent quinacrine or its derivative of
quinacrine mustard, all the chromosomes in the human complement can be paired
and fluorescent patterns distinguished, which can then be analyzed by a
quantitative spectrofluorimetric method.27 This staining method will increase
the accuracy and reduce the time required for making prenatal sex determination,28
though it will probably have to be used in conjunction with the traditional
karyotype analysis.
25E. Boyd, U. Abdulla, I. Donald, J.E.E. Flemming, A.J. Hall, M.A.
Ferguson-Smith, British Medica.l Journal, 1:501, 1971.
26Lele,op. cit., supra, n. 19 at 1317. This point is also supported by
results from the fooTlowing studies, all reported in the British Journal of
Radtlogy, Vol. 45, May 1972: E.T. Coakley, J.S. Slade and J.M. Braeman,
"Exam-nation of Lymphocytes for Chromosome Aberrations After Ultrasonic
Irradiation," pp. 328-332; C.R. Hill, G.P. Joshi and S.H. Revell, "A
Search for Chromosome Damage Following Exposure of Chinese Hamster Cells to
High Intensity, Pulsed Ultrasound," pp. 333-334; and P.L. Watts, A.J. Hall,
and J.E.E. Flemming, "Ultrasound and Chromosome Damage," pp. 335-339.
27For a more detailed explanation of this technique, see D.A. Miller,
P.W. Allerdice, O.J. Miller and W.R. Breg, "Quinacrine Fluorescence Patterns
of Human D Group Chromosomes," Nature, 232:24-27, July 2, 1971. Another
staining technique that does not require fluorescence microscopy has been
described by Maximo E. Drets and Margery W. Shaw, "Specific Banking Patterns
of Human Chromosomes," Proceedings of the National Academy of Sciences of
the U.S.A., 68:2073-77, September 1971.
28Interview with Cecil B. Jacobson, supra, n. 12. See also A. Rook,
L.Y. Hsu, M. Gertner, K. Hirschhorn, "Identification of Y and X Chromosomes
in Amniotic Fluid Cells," Nature, 230:53, March 5, 1971.
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Perhaps the most intriguing implication of the application of fluorescent
staining is the observation of individual variation in the staining of the
autosomes (a chromosome other than a sex chromosome).29 If, as these results
seem to indicate, the bands of particular chromosomes differ from one
individual to another, then it might be possible to derive information from
the chromosome directly that has heretofore only been inferred or inaccessible.
For instance, in families with Huntington's chorea, a disease which does not
manifest itself until after an individual has completed his reproductive years,
it might permit the identification of those who are not gene carriers and thus
free them to have children without risk. Of course, it will also allow the
identification of those who are gene carriers; this raises sensitive problems
for genetic counseling.30 However, much more research into the technical
aspects of this capability remains to be done before such identifications can
be made. More imminently, however, this technique will make possible the
observance of previously undetectable chromosomal translocations. 31
D. Amnioscopy: This method permits direct visualization with a special
conical endoscope of amniotic fluid. It has been used to facilitate
intrauterine transfusion in fetuses with hemolytic disease and might be useful
29P.L. Pearson, M. Bobrow, and C.G. Vosa, "Technique for Identifying
Y Chromosome in Human Interphase Nuclei," Nature, Vol. 226, 1970, p. 80.
A discussion of this possibility can be found inLrancet, 1: 275-276,
February 6, 1971.
Arthur D. Bloom, "Induced Chromosomal Aberrations: Biological and
Clinical Significance," The Journal of Pediatrics, Vol. 81, July 1972, p. 3.
11
in recognizing gross fetal malformations or in obtaining fetal blood
samples. 32
E. Fetal Electrocardiography: This technique may be helpful for
diagnosing potential genetic disorders, since changes in the heart rate "usually
precede biochemical abnormalities rather than follow them."33  It can also be
employed to detect multiple pregnancies.
F. Fetal Sex Determination: Approximately 15 sex-linked genetic disorders
can now be diagnosed prenatally.34 However, at least 150 such disorders have
35
been identified, which means that the management of most of these diseases will
depend upon the accurate determination of fetal sex. For example, in the case
of hemophilia, where no distinction can yet be made between affected and normal
males in utero, the disease could be prevented by prenatal sex determination if
the mother were a heterozygote. Abortion of all male fetuses, whether affected
or not, would guarantee that only normal daughters would be born.36
Amniocentesis provides a reliable method of determining fetal sex.
Examination of cell nuclei for sex chromatin bodies (Barr bodies)37 provides
an inexpensive aid for diagnosing sex chromosome abnormalities. This method
32Orlando J. Miller, "Intrauterine Diagnosis," in F. Clark Frazer and
V.A. McKusick (eds.), Congenital Malformations: Proceedings of the Third
International Conference, The Hague, The Netherlands, September 7-13, 1969,
p. 351.
33Sheldon B. Korones, High-Risk Newborn Infants, (The C.V. Mosley Co.:
St. Louis, 1972), p. 15.
341nterview with Cecil B. Jacobson, supra, n. 12.
35McKusick, op. cit., supra, n. 1 at ix.
36Aborting clinically normal male fetuses, of course, raises its own
moral questions.
37
The presence of the sex chromatin (Barr) body indicates a female.
Its absence indicates a male.
12
is 100 per cent accurate, with two weeks required for developing the culture.38
Fluorescent staining will reduce the diagnostic time to one day, but the level
of accuracy may not be guaranteed.39
II. Techniques for Genetic Screening
If prenatal diagnosis and selective abortion were combined with
screening programs to identify heterozygous carriers, it would be possible to
reduce the incidence of some recessive diseases. If screening procedures
could identify couples in which both man and woman were carriers, the couple,
after assessing the possibility of their having an affected child, could choose
to abstain from having children or assume the risks involved in a pregnancy.
In the latter case, the preganancy could be monitored by amniocentesis and if
the fetus were diagnosed as homozygous, an abortion could be performed.
Numerous large-scale screening programs for the detection of certain
recessive disorders have begun to appear in the United States. For example,
Tay-Sachs disease, a fatal cerebral degenerative disorder, can be detected in
its heterozygoue state by simple and rapid blood40 and urine tests.41 If
necessary, amniocentesis can be used to monitor a pregnancy. The sickle-cell
anemia trait can also be identified through a simple screening procedure which
38Interview with Cecil B. Jacobson, supra, n. 12.
39A recent study has pointed out some of the technical problems involved
in relying on fluorescent staining for sex determination. See A. Rook, et. al.,
op. cit., supra, n. 28.
40Jo Cohen, "New Aid for Tay-Sachs," Washington Post, July 16, 1972,
pp. 9 and 14.
41R. Navon and B. Padeh, "Urinary Test for Identification of Tay-Sachs
Genotypes," The Journal of Pediatrics, 80: 1026-20, June 1972.
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requires only a small sample of blood.42 However, there is not yet a proven
method for detecting the sickle-cell homozygote in utero. Thus, unlike
Tay-Sachs disease, abortion may not be a real alternative for carrier couples.
The detection of heterozygous carriers is now possible for approximately 60
recessive genetic diseases43 and it is likely that more funds will be made
available and new screening programs implemented. Postnatal screening for
sex anomalies can also be done quickly and accurately from buccal smear
preparations (from the mouth) and the application of fluorescent staining to
detect Barr Bodies should facilitate the screening of large populations.44
Screening programs which permit identification of the homozygous child
after birth could, in the case of some disorders and if the diagnosis is made
in time, permit proper treatment and care. The most frequently cited example
is phenylketonuria (PKU), a disease caused by the absence of the enzyme
responsible for the conversion of the essential amino acid, phenylalanine.
Virtually all affected individuals experience mental retardation. If
diagnosed early enough after birth, a special diet may result in the prevention
45
of such retardation. The incidence of PKU and/or hyperphenylolaninemia
42The U.S. Congress recently passed the "National Sickle-Cell Anemia
Control Act," PL 92-294, May 16, 1972, which provides for $25 million for
the fiscal year ending June 30, 1973, with $40 million and $50 million provided
for the following two years. In addition, at least 12 states and the District
of Columbia have enacted laws implementing some type of sickle-cell screening
program.
43
Bentley Glass, Letter to the Editor, Science, Vol. 173, July 9, 1971,
p. 104.
44McKusick, op. cit., supra, n. 8 at 2.
45There is still much controversy over the reliability of existing
diagnostic tests and the appropriateness of various treatments. (See infra,
pp. 59-60.
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has been estimated at 1 in 10,000 births46; at least 41 states have statutes
which provide for the screening of the disease.47 Finally, screening programs
may serve a more immediate need for carriers of certain diseases and for those
individuals whose genetic susceptibility to environmental agents is great. For
instance, there is a growing body of evidence which shows that sickle-cell
anemia in its heterozygous state is not the benign condition that it once was
thought to be.48 Thus, identification of the sickle-cell carrier (and perhaps
of other disorders as well) 49 might make it possible to institute appropriate
measures for therapy and care. Furthermore, some individuals possess a high
46Benjamin White, "Case Finding of Phenylketonuria As a Public Health
Approach," in J.A. Anderson and K.F. Swaiman (eds.), Phenylketonuria and Allied
Metabolic Diseases, Proceedings of a Conference held in Washington, D.C.,
April 6-8, 1966. (U.S. Department of Health, Education, and Welfare, Children's
Bureau, 1967), p. 152.
47Samuel P. Bessman and Judith P. Swazey, "Phenylketonuria: A Study of
Biomedical Legislation," in E. Mendelsohn, J.P. Swazey and Irene Taviss (eds.),
Human Aspects of Biomedical Innovation, (Harvard University Press: Massachusetts,
1971), p. 58.
48
For evidence supporting this position see S. Brown, A. Merkow,
M. Wiener and J. Khajezdeh, "Low Birth Weight in Babies Born to Mothers with
Sickle-Cell Trait," The Journal of the American Medical Association, 221:
1405-08, September 18, 1972; and S.R. Jones, R.A. Binder and E.M. Donowho,
"Sudden Death in Sickle-Cell Trait," The New England Journal of Medicine,
282 (Suppl. 6): 323, 1970.
49Thalassemia, or Cooley's Anemia, is another example. It is possible
for carriers of the trait to be diagnosed as having mild iron deficiency anemia
and given iron to correct the deficiency. Iron, however, is "contraindicated
in thalassemia trait. It can be bad for the patient." Howard Pearson,
quoted in B.J. Culliton, "Cooley's Anemia: Special Treatment for Another Ethnic
Disease," Science, Vol. 178, November 10, 1972, p. 593.
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genetic susceptibility to certain environmental agents. More screening
tests are becoming available which will forewarn these individuals so that they
can reduce their exposure to such risks.
III. Current Therapeutic Techniques
Much of the value of prenatal diagnosis and genetic screening programs
will be contingent upon the availability of effective medical treatment. If
such treatment is not available, however, the alternative of therapeutic
abortion is usually considered.
A. Medical Treatment: As a result of recent scientific and medical
advances, many heriditary disorders which previously had been considered
incurable can now be prevented or controlled. Hemolytic disease of the fetus
and newborn occurs once in 150-200 full-term pregnancies in the United States
and each year an estimated 200,000 women face the possibility of having an
affected child.51 The disease involves the Rh incompatibility between mother
and fetus and leads to severe anemia, brain damage and possible death of the
fetus. The development of Rh immunoglobulin makes it possible to prevent the
isoimmunization of an Rh negative woman to the Rh factor in her fetus. Thus,
"the incidence of hemolytic disease of the fetus and newborn due to Rh
isoimmunization can be practically eliminated once the present generation of
sensitized women has passed the childbearing age." 52
50For some examples of genetic disorders susceptible to environmental
agents, see V.E. Headings, "Genetic Susceptibility to Deleterious Effects of
Environmental Factors," Medical Annals of the District of Columbia, Vol. 41,
September 1972, p. 556.
51Jane S. Lin-Fu, Hemolytic Disease of the Fetus and Newborn Due to Rh
Isoimmunization, (U.S. Department of Health, Education and Welfare, Maternal
Child Health Service, 1969), p. 5.
52Ibid., p. 12.
16
The capacity to treat other genetic diseases is somewhat more limited.
Common modes of treatment include surgery, diet and drug therapy, transplantation,
and enzyme induction. The disorder called heriditary spherocytosis can be
corrected by a surgical procedure, splenectomy, and plastic surgery has made
less visible the effects of cleft lip malformations. Special diets permit
the treatment of several metabolic disorders. For example, galactosemia is
a disease in which the ingestion of milk sugar leads to stunted physical and
mental growth and cataracts. These effects can be ameliorated by replacing
milk with a synthetic formula containing cane sugar. In phenylketonuria,
a reduced phenylalanine diet may substantially reduce the effects of the
disease. Common drug therapy includes the injection of insulin to treat
diabetes and of vitamin B12 to treat pernicious anemia. Such dietary and
drug therapy permits many people to live a much more tolerable life than would
otherwise be possible, though there is actually no real "cure" of the basic
genetic abnormality.
Transplantation may play an important role in treating some genetic
disorders. In diseases such as thalasemia which affect the blood-forming
organs, the transplantation of normal marrow may be an effective treatment.
As with all transplants, however, there remains the problem of finding donors
with genetically compatible tissue types.
The induction of certain enzymes by drugs can be useful in treating
certain diseases. For example, the missing enzyme in hereditary jaundice
can be stimulated by the introduction of phenobarbital. There have also been
attempts to supply directly the deficient enzyme, but there are still several
17
technical problems associated with this procedure.53
While there has been substantial progress in developing different modes
of therapy, most genetic diseases do not respond to such treatment. Even
when disease management seems to be effective, there are concomitant problems
to be considered. For instance, diabetics treated with insulin experience
an increased incidence of vascular disorders compared to the normal
population.54 It has also been determined that the developing infant in a
phenylketonuric woman is exposed to high concentrations of phenylalanine
metabolites and, as a result, may experience mental and physical growth
retardation and heart defects.55 Thus, these constraints have encouraged
attempts to develop a technology capable of treating genetic disease at a
more basic level.
B. Gene Therapy: There are a number of promising techniques for treating
genetic diseases at the genetic level. Although a detailed discussion of
these techniques is beyond the scope of this paper, a brief overview follows.
If one could solve the problem of rejection, it might be possible to
modify the genetic makeup of a tissue by cell replacement therapy. This
involves taking cells or organs from a normal person and transplanting them
53T. Friedmann and R. Roblin, "Gene Therapy for Human Genetic Disease,"
Science, Vol. 175, March 3, 1972, p. 950.
54S. Pell and C.A. D'Alonzo, "Factors Associated with Long-Term Survival
of Diabetics," Journal of the American Medical Association, 214: 1833-1840,
December 7, 1970.
55R.E. Stevenson and R.R. Howell, "Some Medical and Social Aspects of
the Treatment for Genetic-Metabolic Diseases," The Annals of the American
Academy of Political and Social Science, Vol. 399, January 1970, pp. 34-35.
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into the person with a genetic disease. The normal cells would then either
supplement the missing compound or completely take over the function of certain
differentiated cells.56
An alternative to the above approach would be to supply the correct DNA
to the defective gene. The most common method used to implement this approach
is the introduction of new genes into mammalian cells. Current research
indicates that animal viruses,57 bacterial viruses,58 and cell fusion
techniques59 are all capable of introducing new functional genes into
mammalian cells. All of these techniques, however, are hampered by technical
difficulties.60 One problem involves directing the DNA material into the
correct cell. There is also the failure of the added DNA to become permanently
61fixed with the existing DNA of the recipient cells. Although the technology
is still in the experimental stage, current research provides strong evidence
to indicate that it will eventually become possible to transfer genes between,
56Ernst Freese (ed.), Fogarty International Center Conference Report:
The Prospects of Gene Therapy, (U.S. Department of Health, Education and
Welfare, Publication No. (NIH) 72-61, May 1971), p. 2.
57P.K. Qasba and H.V. Aposhian, "DNA and Gene Therapy: Transfer of Mouse
DNA to Human and Mouse Embryonic Cells by Polyoma Pseudovirons," Proceedings
of the National Academy of Sciences of the U.S.A., 68:2345-2349, October 1971.
58Carl R. Merril, Mark R. Geier and John C. Petricciani, "Bacterial
Virus Gene Expression in Human Cells," Nature, 233:398-400, October 1972.
59A.G. Schwartz, P.R. Cook, and H. Harris, Nature New Biology, 230:5,
1971.
60For a discussion of these problems, see Friedmann and Roblin, op, cit.,
supra, n. 53 at 950-953.
61Recent experiments suggest that these problems may soon be resolved.
See Merril, et. al., op. cit., supra, n. 58.
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and insert them into, mammalian cells.
Perhaps the greatest limitation on the use of gene therapy is the lack
of knowledge regarding the fundamental genetic and regulatory processes of
cells. According to one eminent biologist, "Far too little is known about
possible dangers in this field to permit manipulations that might cause
62
permanent distortion of generations of human beings . ." It might be
helpful to ask what defects are of such gravity as to justify intervention?
What might be the consequences of such intervention? For example, some genes
may provide a selective advantage on heterozygous carriers Heterozygotes for
sickle-cell anemia are less prone to infection with malaria. Could the
same be true with other genes? Could the cure be worse than the disease?
There also "exists the possibility that groups of genes have been selected
together, that is, they are co-adapted, and if one excises one of them, the
effects may be greater than desired for the whole group of genes, some
beneficial and some disadvantageous."63 In light of present knowledge, there
is a real problem in interpreting the effects of selection for or against
particular genes.
Another difficulty applies to those diseases which are multigenic and
are a result of combined hereditary and environmental conditions. Schizophrenia,
manic-depressive illness and some forms of cancer are examples of diseases in
62M.R. Pollock, "Molecular Genetics: Short-Term Application and Long-Term
Possibilities," in Watson Fuller (ed.), The Biological Revolution, (Anchor
Books: New York, 1972), p. 92.
63William J. Schull, "Population Genetics," in Arthur G. Steinberg (ed.),
Conference on Genetic Disease Control, (Department of Health, Education and
Welfare, National Institute of General Medical Services, February 1972), p. 33.
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which genetic factors play an important part, but in which environmental
forces are also at work. It is difficult to single out those genes responsible
for these disorders. Even if they could be isolated and treated, environmental
influences might be so strong that the effect of such treatment would be
nullified. And finally, there is the fear that "uncontrolled tumor-like
growth could easily be the consequence of introducing additional chromosomes
64
or a host of viral genes." At the present level of knowledqe, then, a
measure of caution might be the best "medicine" when applying gene therapy.65
66
C. Sex Predetermination: The ability to predetermine sex will make
possible the minimal perpetuation of sex-linked diseases, such as hemophilia
and muscular dystrophy. If the X and Y fractions of semen could be separated,
then insemination with either fraction would virtually assure control of the
sex of offspring.
D. Abortion: For most genetic deseases there is no effective treatment
or cure. Hence, if a defect is diagnosed in utero, an abortion offers a
possible alternative.67 The preferred technique for abortion prior to the
64M.S. Fox and J.W. Littlefield, "Reservations Concerning Gene Therapy,"
Science, Vol. 173, July 16, 1971, p. 195.
65For some ethico-scientific criteria regarding the application of thesetechniques, see Friedmann and Roblin, op. cit., supra, n. 53 at 953-954.
I have discussed both the technology and the potential consequences
of predetermining sex elsewhere. See my monograph The Public Policy Dimensions
of Artificial Insemination and Frozen-Semen Banking, (forthcoming, TheProgram of Policy Studies in Scienceand Technology, The George Washington
University, Washington, D.C.)
I recognize that abortion raises difficult social and ethical problems.Such problems, however, are beyond the scope of this paper and abortion iscited here simply to indicate that it is one additional alternative for
responding to genetic disease.
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first 12 weeks of pregnancy is dilation and suction evacuation. After 12
weeks gestation, an injection of a hypertonic saline solution is the most
common method.68 While there are possible complications associated with
these methods,69 there is a minimum of risk to the patient.
One factor which will help to determine whether or not abortion will be
a real alternative for controlling genetic disease is the legal status of
abortion. On January 22, 1973, the U.S. Supreme Court decided that the
constitutional right to privacy is broad enough to limit the power of the states
to regulate abortion decisions and the conditions under which they may be
carried out, but that the right is not absolute. The Court divided pregnancy
into three stages and balanced the woman's right to privacy against the State's
interests in maternal health and in potential health. The Court ruled that
a woman had an absolute right during her first three months
of pregnancy to decide whether to bear her child. Between
the third and seventh months of pregnancy the states have
the power to regulate the medical aspects of abortion. After
the 26th or 27th weeks of pregnancy, the states may forbid
all abortions e~ ept those essential to save the mother's
life or health.'
The Court further facilitated a woman's efforts to obtain a medically approved
abortion by striking down state residency laws for abortion services and
eliminating procedural rules, such as requirements that abortions be approved
68Selig Neubardt and Harold Schulman, Techniques of Abortion, (Little
Brown & Co.: Boston, 1972).
69Edward A. Duffy, The Effect of Changes in the State Abortion Laws,
(U.S. Department of Health, Education and Welfare, Maternal and Child Health
Service, February 1971), pp. 8-9.
70Washington Post, January 23, 1973, pp. Al-2. Also included in the
Court's opinion was the decision that a fetus is not a person under the
Constitution and thus has no legal right to life.
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by a special hospital committee, that have caused delays for women seeking
official approval. As a result of the ruling, therefore, restrictive state
anti-abortion laws have been declared unconstitutional. 71
APPLYING GENETIC TECHNOLOGY
The techniques reviewed in the previous section have improved considerably
man's capability for controlling genetic disease. At the same time, however,
their application raises new and complex issues. Ouestions concerning "when"
and "how" genetic technology will be employed and who will be its "employer"
are fraught with legal, social, ethical and political ramifications. And
whether the answers to these questions will be framed within the context of
long-range societal goals or the immediate amelioration of individual or
family problems will have important consequences for developing policy. The
remainder of this paper will explore some of these issues, emphasizing the
variables which contribute to their complexity.
I. Treating Genetic Disease
Two modes of therapy should be considered: current medical treatment
and gene therapy. In the case of the former, most would agree that if an
appropriate treatment is available it would be morally reprehensible not to
provide it to all those in need. Modern medicine, guided by man's compassion
for man and its commitment to the individual, makes no distinction between the
sources and types of diseases or the individual "worth" of its patients.
71Even the four states 
-- Alaska, Hawaii, New York and Washington 
-- thathave permitted unrestricted abortions will probably have to alter their laws.These states have residency requirements which the Court struck down.
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Prevailing professional and social mores "demand that all persons have
recourse to all reasonable medical expertise . . ."72 Providing proper care
to all those in need, however, is not without its consequences.
A. Cost of treatment: One problem is the cost involved in providing the
treatment. In the case of cystic fibrosis, the most common autosomal
recessive defect in the white population, a recent study found that the costs
were so high that "families who have been able to attain a moderate income
. . . may be reduced to the poverty level by chronic health problems 73
The study also revealed the inadequacy of private health insurance, with the
finding that 31 per cent of the children "were unprotected by medical insurance
and only one-fourth had sufficiently comprehensive coverage to include
outpatient expenses and medication."74 Another example is hemoohilia, for
which the cost of treatment can be $12,000 per year for each hemophiliac or
approximately $480 million for all Americans suffering from the disease.75
Most American families would be unable to afford such treatment. Should the
72Stevenson and Howell, op. cit., supra, n. 55 at 31.
73
Audrey T. McCollum, "Cystic Fibrosis: Economic Impact Upon the Family,"
The American Journal of Public Health, Vol. 61, July 1971, p. 1340.
74 Ibid. When insurance was available to families on an independent
basis, the study found the cost of premiums to be as hiqh as 40-50 per month.
Blue Cross has established a system under which families having a child with
Cooley's Anemia can be reimbursed for transfusion costs even when their child
is treated as an outpatient. The plan is being set up on a one-year trial
basis and judgment regarding its effectiveness must be reserved until the end
of that time. See B.J. Culliton, OD. cit., supra, n. 49 at 591.
75 K.M. Brinkhous, "Changing Prospects for Children With Hemophilia,"
Children, Vol. 17, November-December 1970, p. 222.
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cost be absorbed by society? Can society then require that to receive such
treatment a patient must fulfill certain conditions?
A recent case in Pennsylvania emphasizes the implications of the latter
question.76 A mother was initially informed by state officials that in order
to receive treatment for her 12-year-old hemophiliac son she would have to go
on welfare. The requirement was subsequently rescinded by the governor, who
then told the family that they would have to recruit 36 donors a month and
drive 100 miles to Philadelphia to donate blood in exchange for their son's
treatment. The family, understandably perturbed, is now involved in
negotiating a compromise with the State.77 One must seriously question the
intent of imposing such conditions on a family. Are there acceptable limits
to such conditions? What criteria should be used for determining those limits?
And with whom does that responsibility rest? A recent court suit demonstrates
the challenge that lies ahead. Four young hemophiliacs have filed suit in
federal court demanding that the government provide them and all other
hemophiliacs in the country with the treatment necessary to allow them to
bleed normally. The suit contends that the youths were denied the "equal
protection" guaranteed by the 14th Amendment, citing the government maintenance
programs for drug addicts.78 Thus, the familiar problem of allocating resources
becomes even more acute with the emergence of new genetic technology.
76The following account is taken from articles appearing in the
Washington Post, November 2, 1972, p. K3 and November 6, 1972, p. A20.
77As a result of this incident, it was recently announced that
Pennsylvania had established a program to give free treatment ot hemophiliacs.
See the Washington Post, December 5, 1972, p. A4.
78Washington Post, October 11, 1972, p. A18.
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B. Health Consequences of Treatment: Another unanticipated consequence
associated with treating genetic disease can be illustrated by examing the
treatment for PKU. As already noted (supra, p. 17), the fetus of a
phenylketonuric woman is exposed to high concentrations of phenylalanine
metabolites and, as a result, it may experience severe retardation and heart
defects.79 Thus, the medical science which enabled those mothers to lead
relatively normal lives now threatens to deny their children the same benefits.
Theoretically, correction of the metabolic disorder should prevent damage to
the fetus. From a medical standpoint, however, reinstatement of the low
phenylalanine diet poses two problems. First, "the health status of the
phenylketonuric woman may not justify the difficulties involved in attempts
80
to control diet." And second, there is the possibility that reinstatement
of the diet may "result in nutritional deficiency which may be as detrimental
to the fetus as maternal phenylketonuria itself."81 Under these circumstances,
should the mother be encouraged not to conceive at all? If she insists on
having a child, what is the physician's responsibility with reqard to
reinstating the special diet? Since the birth of such irreparably damaged
children will result in life-long institutional care, does society have a right
79According to R.R. Howell and R.B. Stevenson, "virtually every infant
born to a woman who meets the criteria for classic phenylketonuria will
have major defects, with growth retardation and microcephaly as well as other
structural abnormalities." "The Offspring of Phenylketonuric Women," Social
Biology, Vol. 18 (Supplement, 1971), p. S27.
80V. Elving Anderson, "Discussion: Maternal Effects in Genetic Disease,"
Ibid., p. S32.
R.O. Fisch, D. Doeden, L.L. Lansky and J.A. Anderson, "Maternal
Phenylketonuria: Detrimental Effects on Embryogenesis and Fetal Development,"
American Journal of Diseases of Children, Vol. 118, December 1969, p. 855.
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to intervene in preventing such births? The consequences noted for PKU have
been linked to other maternal disorders as well,82 Thus increasing the
proportions of the problem.
C. Treatment by Gene Therapy: Although the development:and application
of techniques for gene therapy are a number of years into the future, their
potential impact warrants serious consideration at this time. The high degree
of uncertainty and potential risks involved in using gene therapy clearly
distinguish it from more conventional modes of therapy. Perhaps even more
important, however, is that both the uncertainty and the risks will affect
future offspring as well as the present generation. Friedmann and Roblin
write that "For an acceptable genetic treatment of a human genetic defect, we
would require that the gene therapy replace the functions of the defective
gene segment without causing deleterious side effects in the treated individual
83
or in his future offspring." They conclude that "although the ethical
problems posed by gene therapy are similar in principle to those posed by
other experimental medical treatments, we feel that the irreversible and
heritable nature of gene therapy means that the tolerable margin of risk and
uncertainty in such therapy is reduced." 84 They support the need for continued
research into the technology of gene therapy and propose eithico-scientific
criteria for applying these techniques. However, they oppose using gene
therapy in human patients at this time because of man's limited understanding
of genetic processes and of how they might be affected by technological
82Stevenson and Howell, o. cit., suDra, n. 55 at 35.
83 Friedmann and Roblin, op. cit., supra, n. 53 at 952.
84 Ibid., p. 953.
28
should be prohibited or encouraged? What criteria or guidelines should be
used for determining those conditions? And with whom do these responsibilities
rest? These questions challenge both the scientific and ethical dimensions
of the policy-making process.
D. Treatment and the Gene Pool: Perhaps the most frequently cited
consequence of treating genetic disease is its impact on the human gene pool,
i.e. the total genetic information possessed by the reproductive members of
the population. The present gene pool is the result of 3 billion years of
evolution and natural selection. Nature is successful in protecting the human
species from detrimental genes because potential carriers either die prior to
reproducing or reproduce less frequently than other heriditary types. The
problem, as viewed by a growing number of people, is that medical advances
have altered this situation by reducing the impact of natural selection. New
treatment permits the survival and reproduction of persons with inheritable
disorders who in earlier times would not have reproduced. As a result, the
human gene pool experiences a higher frequency of many defective genes. For
example, approximately 90 per cent of the children who formerly died from
retinoblastoma - a malignant tumor of the eye - are now surviving because
of advances in surgery and chemotherapy. Many of these children will be blind,
but certainly able to reproduce and, consequently, to transmit the deleterious
gene to their progeny.88 Gene therapy which did not affect reproductive cells
would produce similar results. Treated individuals would still pass the
88Reisman and Matheny, op. cit., supra, n. 15 at 205.
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intervention. 85 The tone of their presentation, however, suggests that gene
therapy should and will become a useful method for medical treatment.
Theologian Paul Ramsey, however, is less certain about the use of such therapy.
He writes that "the unknown and unforeclosed risks to future generations may
outweigh any benefit that might be secured for the individual patient. In a
matter of such grave importance, 'no discernible risk' is not adequate
protection. We need to know that there are no risks - a requirement which
86
inheritable gene therapy is not apt to meet." Ramsey is undoubtedly correct
when he contends that complete knowledge regarding the possible risks of gene
therapy is unlikely ever to be realized. Under such circumstances, then, gene
therapy affecting future generations would be prohibited if Ramsey's criterion
was observed. Ramsey believes that the choice is not simply between doing
nothing about an inherited disease and correcting it by gene therapy.
Alternative choices would include "having no children or fewer children. The
treatment would be continence or not getting married or using three
,,87
contraceptives at the same time or voluntary sterilization."87 In light of
the uncertainty and high risks involved in gene theraDy, Ramsey finds more
acceptable these other alternatives for "treating" genetic disease.
The two points of view outlined above converge at the crucial policy
questions: Are there any conditions under which certain types of gene therapy
85Ibid., p. 954.
86Paul Ramsey, "Genetic Therapy: A Theologian's Response," in Michael
Hamilton (ed.), The New Genetics and the Future of Man, (Wm. B. Eerdmans
Publishing Co.: Michigan, 1972), p. 169.
87Paul Ramsey, Fabricated Man, (Yale University Press: New Haven, 1970),
p. 118.
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defect on to their offspring, thus requiring more and more gene therapy.
What are the likely consequences if the genetic load is permitted to
increase? According to some, the quality of the gene pool will continue to
deteriorate and greater demands will be placed upon the community's medical
services, since more people will be dependent on medical care and treatment.
Ramsey foresees "some future generation [which] will begin to experience
20 percent genetic deaths."89 And Bentley Glass draws the following scenerio:
to contemplate the man of tomorrow who must begin his day
by adjusting his spectacles and his hearing aid, inserting
his false teeth, taking an allergy injection in one arm and
an insulin injection in another, and topping off his
preparations for l1e by taking a tranquillizing pill, is
none too pleasant.
What is good for today's individual and his generation may be detrimental
to future populations, and unless some action is taken "the whole genetic
capacity of man will be much weakened." 91
This bleak picture has prompted the suggestion of measures designed to
cope with the deteriorating gene pool. Such measures rest on the belief
that the present pattern of genetic selection is much less desirable than
that which could be achieved by a deliberate and controlled effort. Two
types of proposals are frequently suggested. The first is a program designed
89Paul Ramsey, "Moral-Religious Implications of Genetic Control," in
John D. Roslansky (ed.), Genetics and the Future of Man, (Appleton-Century-
Crofts: New York, 1966), p. 111.
90Bentley Glass, "Human Heredity and Ethical Problems," Perspectives in
Biology and Medicine, Vol. 15, Winter 1972, p. 243.
91Julian Huxley, quoted in Sol Tax and Charles Callender (eds.),
Evolution After Darwin, Vol. III, (The University of Chicago Press: Chicago,
1960).
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to alter genetic composition by encouraging desirable traits, i.e. "positive"
92
eugenics. The second is designed to alter genetic composition by reducing
the incidence of undesirable traits, i.e. "negative" eugenics. The latter
alternative might be accomplished by persuading those who have a high
likelihood of transmitting a genetic defect not to reproduce, by sterilization,
or by abortion of fetuses diagnosed as genetically abnormal.
The "deteriorating gene pool" argument is not without its critics. They
contend that the predicted danger of a genetic apocalypse is erroneously
calculated. They see no "imminent danger of being overwhelmed by the bad
genes . . . we would seem to have no reason to fear that the normal population
will soon be replaced by that of individuals with abnormal genetic factors." 93
One force working to reduce the genetic burden is current demographic trends.
"In the short run, demographic trends (in and of themselves) are reducing the
incidence of serious congenital anomalies." 94 Trends indicating smaller
family size and a lowered average age of childbearing will work to ameliorate
the quality of the human gene pool.
Another criticism concerns the nature and severity of genetic disease.
"Many a 'bad' gene whose effects are overcome euphenically [i.e. by medical
treatment] may be said to have lost its 'badness,' wholly or to a large degree
so that its accumulation no longer represents a serious biological load even
See supra, n. 66, for a discussion of the implications of such
programs.
93Reisman and Matheny, op. cit., supra, n. 15 at 204.
94Dudley Kirk, "Patterns of Survival and Reproduction in the United
States," Proceedings of the National Academy of Sciences of the U.S.A.,
Vol. 59, March 1968, p. 669.
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though it may represent a considerable economic load." For example, if a
disease such as diabetes can be controlled by artificially altering the
environment, i.e. providing easy acquisition to insulin, then any real harm
to individuals is negated. Thus, "environmental changes have made some
hereditary defects irrelevant";96 it seems reasonable to expect similar
medical advances in the future.
There are those who also question an underlying assumption of proposals
designed to "protect" the gene pool - that such protection is an obligation
of this generation to future generations. Professor Martin P. Golding contends
that "We are thus raising a question about our moral relations to the community
of the remote future. I submit that this relationship is far from clear,
certainly less clear than our moral obligations to communities of the present."97
It seems highly unlikely that today's generation can accurately predict the
needs and wants of succeeding generations.
One might go so far as to say that if we have an obligation
to distant future generations it is an obligation not to
plan for them. Not only do we not know their conditions
of life, we also do not know whether they will maintain the
same (or a similar) conception of the good life for man as
we do.98
Even if it could be agreed that there are real and identifiable obligations
95Philip Handler (ed.), Biology and the Future of Man, (Oxford
University Press: New York, 1970), pp. 910-911.
96Kirk, op. cit., supra, n. 94.
97Martin P. Golding, "Ethical Issues in Biological Engineering," UCLA
Law Review, Vol. 15, February 1968, p. 453.
98Martin P. Golding, "Obligations to Future Generations," The Monist,
Vol. 56, January 1972, pp. 97-98.
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to future generations, there is still the problem of deciding how to balance
those obligations against the obligations to the present generation.
Any attempt to manipulate the existing gene pool might not only foreclose
possible options of future generations, but might also adversely affect their
biological adaptability. The genetic diversity of the human gene pool has
long been recognized as necessary for ensuring adaptability to future
environments, so essential to survival in the face of constant evolutionary
change. "Genetic diversity is in one sense capital for investment in future
adaptations. Since genetic variability represents evolutionary capability,
it is a load we should be ready and willing to bear."99  It would appear
morally and biologically unwise, then, to tamper with the gene pool signifi-
cantly without prior knowledge of the demands and needs of future environments.
Finally, many seriously doubt the efficacy of negative eugenic programs.
Most deleterious genes are maintained in the population by normal heterozygous
persons. It is estimated that "every individual is a carrier of three or
more of such genes, and that virtually every human being carries at least
,,lO0
one. Since one cannot always be certain that such genes will manifest
themselves clinically in present or future generations, "only by eliminating
virtually everyone could our load of past mutations be eliminated, and this
only temporarily, as new mutations are occurring all the time."
9 9 Marc Lappe, "Moral Obligations and the Fallacies of 'Genetic Control,'"
Theological Studies, Vol. 33, September 1972, p. 423.
100
Arno G. Motulsky, George R. Fraser and Joseph Felsenstein, "Public
Health and Long-Term Genetic Implications of Intrauterine Diagnosis and
Selective Abortion," in Daniel Bergsma (ed.), Intrauterine Diagnosis (Birth
Defects: Original Article Series, Vol. 7: The National Foundation - March
of Dimes, April 1971), p. 26.
101Orlando J. Miller, "Discussion of Symposium Papers," Ibid., p. 34.
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An alternative suggestion for improving the gene pool, without acting
directly upon biological man, is to minimize or eliminate environmental
hazards. It is becoming clear that "we are exposed to a wide range of chemical
and physical agents which may damage the genetic material of our cells."1 02
Thus, to the extent that man contaminates his environment and introduces factors
that render it harmful, "his best interests are served by the adoption and
enforcement of regulatory measures to prevent, minimize, or remove undesirable
103
contamination."
In view of the sometimes vehement stands taken by those on both sides of
the argument, it would seem to be useful to begin to assess the status of the
human gene pool. A six-year report of the American Eugenics Society speaks
directly to this point:
In view of the relative stability of the gene pool,
the problem is not generally viewed as one requiring
dramatic or 'crash' solutions. But in the long run,
changes in the distribution and frequenctes of genes may
be of greatest significance. At this stage the need is
for better identification of the present and potential
direction of changes rather than action to alter these
trends in any major way.104
It is also not too soon to begin to evaluate some of the suggested approaches
for improving man's capability to control genetic disease.
102Bloom, op. cit., supra, n. 31 at 1. See also V.E. Headings, op. cit.,
supra, n. 50.
103National Commission on Community Health Services, Changing Environmental
Hazards, Report of the Task Force on Environmental Health (Public Affairs
Press, Washington, D.C., 1967), p. 20.
104Theodosius Dobzhansky, Dudley Kirk, Otis Duncan and Carl Bajema, The
American Eugenics Society, Inc. Six-Year Report, 1965-1970 (Published byte
Society: New York), p. 6.
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II. Prenatal Diagnosis and Selective Abortion
When prenatal diagnosis is combined with abortion, it becomes possible
to alter directly the course of genetic disease. The introduction of new
automated procedures will facilitate diagnosis as well as lessen its cost.
It is likely, therefore, that as methods for intrauterine diagnosis improve,
that pressures to use them in the management of the pregnant patient will
105
increase. Undoubtedly, this new technical capability will also add another
dimension to the debate concerning abortion. It would be useful, therefore,
to examine some of the criteria for developing policy for this alternative.
A. Risks/Benefits of Prenatal Diagnosis: One important consideration
is the risks involved in using various prenatal diagnostic tests. All of the
techniques described herein carry some degree of risk. While most of the
evidence appears to indicate that the risk is minimal, much more data remains
to be collected and evaluated. In the case of amniocentesis, for example, it
has been suggested that "the current status of knowledge of the biology of
amniotic fluid and its contents - including the fetus - is so rudimentary that
106
this field must be regarded primarily as an area for research." As noted
earlier (supra, p. 7), very little information is available regarding the
long-term risks of applying amniocentesis. Since the use of any diagnostic
technique is justified only if the frequency of the disease or its severity
105
"As couples feel social pressure to limit population growth and to
be content with only two children, most will very much want to ensure that
the two they do have are healthy. I expect the demand for amniocentesis to
develop strongly." C.O. Carter, "Practical Aspects of Early Diagnosis," in
Maureen Harris (ed.), Early Diagnosis of Human Genetic Defects: Scientific
and Ethical Considerations, Fogarty International Center Proceeding, No. 6,
1972. (Department of Health, Education and Welfare, Publication No. (NIH)
72-75), p. 20.
106Orlando J. Miller, op. cit., supra, n. 101 at 33.
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are greater than the risks posed by the diagnostic procedure, a careful
assessment of those risks and the reliability of the diagnosis should be
made.
Because of the danger of applying these techniques to the general
population before their costs - in terms of morbidity and mortality to mother
and fetus - have been reliably assessed, it has been suggested that they be
used only when a couple carries a moderate or high risk of giving birth to
107
a child with a genetic defect. Various criteria for making such determi-
nations have been proposed.108 For example, statistics indicate that
increasing age at pregnancy is correlated with an increased incidence of
chromosomal abnormalities.109 Thus, prospective prenatal diagnosis might be
110
warranted of mothers above a certain age.
As familiarity with these techniques increases, the risks will surely
diminish. Automation will make the required tests simple and inexpensive and
more couples will undoubtedly request them. Thus, by emphasizing the
criterion of risks/benefits, there might well come a time when prenatal
diagnosis will be an integral part of monitoring all pregnancies. There are,
however, other considerations.
B. Parent-Child Relationship: Since treatment or cure is not available
for most genetic deseases, the only therapeutic alternative following the
107Michael M. Kaback, quoted in Maureen Harris (ed.), op. cit., supra,
n. 105 at 85.
108C.O. Carter, Ibid., pp. 18-19.
109Luks and Ruddle, op. cit., supra, n. 9 at 495-497.
In the case of Down's syndrome, for example, a substantial proportion -
as high as 33 per cent - of children are born to mothers above the age of 40
years. Motulsky, et. al., op. cit., supra, n. 100 at 30.
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diagnosis of a defective child is an abortion. Important to consider here
is the effect that the wide-scale application of prenatal diagnosis combined
with abortion will have on the parent-child relationship. Ethicist John
Fletcher contends that
the experience of parents in prenatal diagnosis and genetic
counseling does not lessen the affection they bear for their
children, already born or to be born, even though that
relationship is permanently altered by the character of the
experience of genetic counseling and amniocentesis.I1 l
(emphasis added)
In his efforts to identify and describe this "altered relationship,"112
Fletcher suggests that a new stage of life is created, in which parents will
be as intimate with their children before they are born as they are after
they are born. One result of this was "that active roles as parents began
earlier in the course of pregnancy . . . Assurance of the health of the child
releases parental care, planning and symbolic activity usually reserved for
birth.113 Fletcher quotes a number of couples responding that "they loved
them [their children] more because they had known them longer."114 Ironically,
Fletcher also found that this pre-natal intimacy "increases the sense of
compulsion towards perfection that middle-class people have; they want their
llJohn Fletcher, "The Brink: The Parent-Child Bond in the Genetic
Revolution," Theological Studies, Vol. 33, September 1972, p. 428.
1121Ibid., pp. 457-485. His sample consisted of 25 couples who had
undergone amniocentesis and had given birth to a healthy child or had an
abortion performed.
113 Ibid., p. 477.
114Interview with Dr. John Fletcher, Director of Interfaith Metropolitan
Theological Education, Inc., Washington, D.C., August 11, 1972.
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babies to be healthy, beautiful and perfect." He sees a danger in this,
contending that "the drive towards perfection is one of the worst qualities
116
that human beings have since it causes them to become very intolerant."
Fletcher also asks if prenatal diagnosis,
because it inclines the parents to contemplate the abortion
of the fetus before they are fully informed as to the
results of the test, erode[s] that "basic trust" which
is so fundamental as to lead Erik Erikson to assert that
"the firm establishment of enduring trust over basic
mistrust is the first task of the budding personality
and therefore first of all a task for maternal care"?117
Fletcher contends that even if the diagnostic results are negative, the test
and its results are going to change the lives of the parents. "They will
never be the same parents they were before because this test is changing the
way they learn the roles of parenthood." People have been brought up to
love their child, at least prior to its birth, without preconditions. But,
says Fletcher, "when you start contemplating the tests with the added feature
that abortion is an alternative, you have introduced an element of doubt into
that relationship that has never been there before. So you are a different
parent than you were taught to be."1 19 Thus, genetic technology has altered
parenthood in a way that had not been anticipated.
What will be the effect of this new dimension of parenthood on the "basic
115Idem.
116Idem.
117Fletcher, op. cit., supra, n. 111 at 473.
118Interview with John Fletcher, supra, n. 114
1191dem.
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trust" between child(ren) and parents? Fletcher states that "nobody can
live with the thought that his parents would have killed him if he had been
sick. There is no way to accept that, yet you are going to have a whole
120
generation of parents who have had this opportunity." In the context of
its present usage, Fletcher believes that prenatal diagnosis "does not
introduce a permanently insoluble moral conflict in the ethics of parental
121
caring." But what will be its effect if applied on a wide-scale and
supported by socially and legally sanctioned abortion? Fletcher believes
that
Nothing could weaken or dissolve the parent-child bond
more effectively than children becoming afraid that the
parents made such decisions for trivial reasons of personal
convenience or because they were forced into it for
external societal reasons.122
The parent-child relationship, then, constitutes another important variable
to consider when developing genetic technology policy (see Infra, pp. 63-64,
for additional discussion of intrafamily relationships).
C. Economic Variables: Economic factors must also be considered. The
economic impact can be evaluated on two levels: (1) the burden which falls on
the individual family, and (2) the costs to society. The birth of a genetically
defective child creates new problems of resource allocation for a family. The
cost of caring for such a child can make deep inroads into a family's financial
120
Idem. Fletcher also inquires into the feelings of living children,
e.g. will they worry about their own security?, where amniocentesis was used
on a fetal sibling. Op. cit., supra, n. 111 at 478.
121Fletcher, op. cit., supra, n. 111 at 479.
122Ibid., p. 480.
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resources (witness the case of cystic fibrosis, supra, p. 23) and private
health insurance has been unable to absorb this impact. This drain on
resources might also have disruptive consequences for the family unit in
more subtle ways.123
The costs to society are both direct and indirect. Society not only
assists in providing care for defective individuals, but also assumes the
losses resulting from their inability to become economically and socially
productive members of society. Institutionalization and care for persons
with genetic disorders, many of which are chronic in nature, can be very
expensive. For example, the cost to society of caring for those suffering
from Down's syndrome, which has an estimated frequency of one in 600 births,
is approximately $1.7 billion annually.124 The economic impact of genetic
disease, then, must be weighed along with other factors.
D. Abortion and the Gene Pool: While a program of selective abortion
might help to relieve the emotional and financial strain experienced by
individuals and their families, how effective would such a program be in
reducing the total frequency of deleterious genes? Arno Motulsky and his
colleagues have found that the use of selective abortion to reduce the cases
of autosomal recessive diseases "will be relatively small (between 12.5% and
34%) if the procedure is only initiated following birth of an affected
child." 125  In fact, selection against recessive genes under any conditions
123See McCollum, op. cit., supra, n. 73 at 1335-40, for a discussion of
some of the educational, social and psychological needs of other family
members that might be compromised by the strain on family resources.
124Glass, op. cit., supra, n. 90 at 241.
125Motulsky, et. al., op. cit., supra, n. 100 at 30.
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will be ineffective unless there is also selection against heterozygotes.
For example, "a 50% reduction in reproduction of heterozygotes would reduce
the incidence of the recessive homozygote under random mating to one fourth
its former value in one generation." 126 For maximum effectiveness in
eliminating autosomal recessive diseases, premarital carrier detection
would be required to detect those matings at risk.127
Sex-linked diseases can be prevented by prenatal diagnosis of
heterozygote mothers and selective abortion of all male fetuses. The impact
of such a program, however, would be somewhat softened since many harmful
sex-linked diseases are a result of fresh mutations. Thus, "even with
prospective diagnosis, the maximum case reduction would not exceed two-thirds
of existing affected males for diseases with zero fertility."128 A potential
dysgenic effect of such a program is that aborion of all male fetuses of
heterozygote mothers would result in an increase (as much as 50 per cent
with each generation in the case of hemophilia) 129 in female carriers in
future generations, thus requiring more abortions.
The possibility that selection against autosomal recessive diseases
would lead to an increase in their gene frequency could be the result of
"reproductive compensation," since couples would be inclined to replace the
affected child lost by abortion. A proportion of these compensating children
12 James F. Crow, "Rates of Genetic Change Under Selection," Proceedings
of the National Academy of Sciences of the U.S.A., Vol. 59 March 1968, p.660.
127
Motulsky, et. al., op. cit., supra, n. 100 at 30.
128 Ibid., p. 31.
129Friedmann, op. cit., supra, n. 11 at 40.
41
will be abnormal gene carriers, thus increasing the frequency of abnormal
genes over that which would have resulted had no such program been implemented.
There is evidence, however, that "despite compensation, the total effects
on gene frequency are minimal and are not a cause for concern." 130
A program of selective abortion aimed at reducing the frequency of
harmful genes raises a number of sensitive issues. For example, if a
distinction between affected fetuses and clinically normal carriers cannot
be made, as in the case of hemophilia, half of the male fetuses aborted
would be normal. The moral implications of such a procedure must be weighed
along with other considerations. A concomitant problem resulting from the
inability to distinguish between affected and normal male fetuses in utero
is that the result would be a 75 per cent probability of abortion with each
pregnancy. This would mean a "24% risk that five consecutive pregnancies
131
would be aborted." In this instance, then, the deleterious effect on the
couple involved might be greater than if no such program were introduced.
As noted earlier, abortion of all male fetuses where sex-linked diseases
are indicated would result in an increase in female carriers, thus increasing
the frequency of the harmful gene and the need for abortion. Is there also
justification for aborting female carriers? The abortion of such fetuses is
morally questionable since they exhibit no clinical manifestation of the
disease. From a population and public health point of view, a recent study
132
found little evidence to support such a program. Perhaps such carriers
130Motulsky, et. al., op. cit., supra, n. 100 at 31.
131Michael M. Kaback, "Discussion of Symposium Papers," Ibid., p. 35.
132
Motulsky, et. al., op. cit., supra, n. 103 at 27.
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could be counseled not to reproduce; in this event, the moral and political
overtones of such a policy need to be carefully assessed. Finally, there
are those who believe that the development of new medical techniques for
treating such diseases will make the abortion of such fetuses unnecessary.133
E. Attitudes and Policies on Abortion: Another factor which will
influence the introduction and development of this approach involves existing
attitudes and policies concerning abortion. In a study of 25 couples,
Fletcher found that while "abortion is the major moral problem of parents in
genetic counseling, [they] are inclined to favor abortion in case of a positive
134diagnosis, and they have reached this position prior to counseling." On
a much broader scale, a recent national survey found that majority support
for legal abortion has increased sharply. The survey revealed that 64 per cent
of all Americans support full liberalization of abortion laws, believing that
"abortion should be a matter for decision solely between a woman and her
physician."135 Recent statements by both public and private groups also
reflect a more liberal attitude toward abortion. For example, the Commission
on Population Growth has recommended that "present state laws restricting
abortion be liberalized along the lines of the New York statute [which, prior
133Fritz Fuchs, quoted in Maureen Harris (ed.), op. cit., sutra, n. 108
at 124-125. For example, ten years ago the chances were remote that a baby
with Down's syndrome would live beyond its 15th birthday. Since that time,
however, the development of new antibiotics has given such children a projected
life expectancy of 50 years or more. See Joseph D. Whitaker, "Science Lends
Hand to Mongoloid Baby," Washington Post, December 18, 1972, p. Al
134John Fletcher, "Moral Problems in Genetic Counseling," Pastoral
Psychology, April 1972, p. 60.
135George Gallup, "Abortion Seen Up to Woman, Doctor," Washington Post,
August 25, 1972, p. A2.
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to the recent Supreme Court ruling, was the most liberal of the state abortion
136
laws]." And the World Council of Churches has called for its members
to be prepared to endorse the personal right of parents to
choose an induced abortion to prevent the birth of a gravely
defective child. Wherever the laws of the state make this
illegal, the churches should press for a modification of the
law to permit such options to take place.137
The possibility of using therapeutic abortions for genetic purposes
raises concern among many who fear that in a social climate in which unwanted
preganancy is sufficient indication for abortion, there will be a tendency
for couples to seek abortions for arbitrary and casual reasons.
With increasing acceptance of abortion and limitations on
family size, it is probable that some families will seek
termination of pregnancies that involve less severely affected
fetuses, or those with disorders that are treatable to some
extent . . . . It is also likely that abortion may be chosen
for disorders of uncertain severity. It can in fact be
anticipated that families will not want to rik any departure
from the normal karyotype in their offspring. 38
Perhaps it is appropriate to recall Fletcher's fears regarding the possible
growth in intolerance on the part of future parents (supra, pp. 36-37). Those
who fear the emergence of an "abortion mentality," characterized by an
increasing intolerance for "weakness" or differentiation from a given "norm,"
136The Report of the Commission on Population Growth and the American
Future, Population and the American Future, (U.S. Government Printing
Office: Washington, D.C., March 1972), p. 142.
137Working Committee on Church and Society, op. cit., supra, n. 4 at 6.
138
Aubrey Milunsky, John W. Littlefield, Julian N. Kanfer, Edwin H.
Kolodny, Vivian E. Shih and Leonard Atkins, "Prenatal Genetic Diagnosis
(Third of Three Parts)," The New England Journal of Medicine, Vol. 283,
December 31, 1970, p. 1502. The authors cite the XYY chromosome anomaly
as a disorder of "uncertain severity." The varied scientific opinion
regarding this genetic defect and its consequent policy implications will
be discussed later.
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point to an almost casual acceptance of abortion. This attitude, they maintain,
is reflected in statistics from those states which had liberal abortion laws
and in the growing acceptance of "early-stage abortion," which allows a woman
with a suspected and unwanted pregnancy simply to have her monthly menstrual
period extracted.139 This concern over the effect of a program combining
prenatal diagnosis with selective abortion may be expressed as important
questions for policy: Do acceptable standards for deciding when to abort
need to be established? Whose responsibility is it to develop and apply those
standards? What will be the effect of such a program on attitudes toward
already existing "genetically defective" children?
F. Policy Alternatives: Debate has already begun regarding the types of
policy adjustments that might be made. For example, should a woman be
required to agree to an abortion prior to prenatal diagnosis? Some contend
that "For parents unwilling to take that step, diagnosis of a disease in a
fetus would serve no useful purpose and would only create anxiety and grief
for the parents." 140 Thus, they firmly believe that "the decision to interrupt
the preganacy, if the suspected disorder is verified in the fetus, should be
made before the amniocentesis." 141 Should there be special provisions, however,
for those patients or physicians whose religious convictions preclude an
139For details of the procedure and some of its problems, see Time,
September 11, 1972, p. 47; also the Washington Post,January 26, 1977-,
p. C5.
140
Arno G. Motulsky, "Genetic Therapy: A Clinical Geneticist's Response,"
in Michael Hamilton (ed.), op. cit., supra, n. 86 at 131.
141Fritz Fuchs, "Amniocentesis and Abortion: Methods and Risks,"
op. cit., supra, n. 100 at 19.
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abortion under any circumstances? There are others who find unacceptable
such restrictions on individual decision-making. The use of prenatal
diagnosis does not mean that "the geneticist may abrogate the couple's
decision by assuming that if the fetus is normal she will carry it, or if
abnormal, she will abort. The genetic component is one of many, and the
143
client must be helped to put it in perspective for a positive choice."
With respect to the difficult problem of deciding how "abnormal" a fetus
must be to justify abortion, one geneticist has suggested that society must
take advantage of "all morally acceptable developments that promise to minimize
the number of unfortunate individuals incapable of full participation in this
144
complex society." While this position might attract sympathy, it would
probably draw an equal amount of skeptical criticism. How is one to determine
if a fetus will be "incapable of full participation"? This is a very real
problem, amply illustrated by the case of Down's syndrome
Some Down's children have rather gross retardation,
major heart anomalies, and many fail to survive infancy;
on the other hand, some have a rather mild retardation .
no major heart defects, and have lived to at least middle
age. An individual carrying a gene or genes which cause
1420f relevance here is a resolution (S.J. Res. 64) recently introduced
by Senator Frank Church, which would make it national policy, in the
administration of all Federal programs, to protect physicians and health
care personnel in their exercise of religious or philosophical beliefs
which proscribe the performance of abortions or sterilization Drocedures.
Congressional Record, February 15, 1973, pp. S2567-68.
143E. James Lieberman, "Psychological Aspects of Selective Abortion,"
Ibid., p. 20.
144James V. Neel, "Lessons from a 'Primitive People,'" Science, Vol. 170
November 20, 1970, pp. 820-21.
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retardation may be more or less retarded depending on other
genetjc factors and the external environment which is at
work. 45
Furthermore, many Down's children have been found not to suffer and to have
146
good emotional adjustment. Thus, it would be difficult to determine an
absolute measure of biological fitness, since such fitness is to some extent
dependent on a particular environment.
A policy question which pervades all others concerns the basis upon
which society will allocate decisions to either personal conscience or public
choice. At what point is society's intervention into individual decision-
making justified? As prenatal diagnosis becomes more widespread, the tensions
resulting from its application will become more acute. There is a need to
relieve those tensions, balancing individual and societal needs with the
proper respect for human life.
III. Screening for Genetic Disease
If prenatal diagnosis and selective abortion were combined with
screening programs designed to detect heterozygous carriers, it might be
possible to realize significant reductions in the incidence of some recessive
diseases. If at-risk parents were identified prior to reproduction, they
could eliminate the risk by remaining childless, by adopting their family,
or, when available, by artificial insemination or prenatal diagnosis. Another
advantage of such programs is that the detection of the homozygous child
after birth might be followed by immediate treatment, thus reducing and perhaps
eliminating the deleterious effects of the disease.
145Robert C. Baumiller, "XYY Chromosome Genetics," Journal of Forensic
Sciences, Vol. 14, October 1969, p. 417.
146Karen Lebacqz, Letter to the Editor, The Hastings Center Report,
Vol. 2, February 1972, pp. 12-13.
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A. Cost/Benefits of Screening: Cost/benefit analysis has shown that
screening programs would result in large savings for both the family and
society. For example,
The cost for successful medical treatment of phenylketonuria
is estimated to be no more than one tenth the cost of care
for a retarded patient in an institution. Early diagnosis
and treatment thus saves the community about $9,000 annually
per patient. Moreover, the patient who escapes the immediate
consequences of this mutant allele will eventually earn
income and pay taxes, representing a further benefit to the
community.147
In the case of detection prior to birth, a recent study demonstrated that
in the case of cystic fibrosis, a substantially favorable economic ratio
148
would result. As new screening techniques become available an important
part of planning large-scale screening programs should be the assessment of
the costs involved in treating the genetic diseases. Present evidence seems
to indicate a substantial economic saving.
B. Screening and the Gene Pool: Another important criteria for assessing
the value of screening is its potential for reducing the frequency of
deleterious genes. The underlying assumption of such a program is that
heterozygous couples will not mate, or in instances where they do, they will
not have their own children. It has been suggested that this latter alternative
is best realized through a program of voluntary sterilization. It should be
useful, therefore, to review the potential impact of these two-approaches on
the gene pool.
If the fertility of heterozygotes and normal individuals were identical,
147
Charles R. Scriver, "Screening for Inherited Traits: Perspectives,"
in Maureen Harris (ed.), op. cit., supra, n. 105 at 95-96.
148Motulsky, et. al., op. cit., supra, n. 100 at 30.
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the frequency of the abnormal gene would remain constant. However, many
genes which result in autosomal recessive diseases owe their high frequency
to the heterozygote's advantage in fertility or mortality. If heterozygotes
were to cease mating with one another and this advantage persisted, there
would be an increase in the genes since heterozygotes would have a greater
average number of children. Consequently, the
gene loss previously incurred by infertility or early death
in homozygotes would cease. In the case of cystic fibrosis
persistence of the assumed heterozygote advantage for about
100 generations would increase the frequency of carriers in
white populations from 5% (its present level) to 50%. 149
If there were little or no difference in fertility between heterozygotes and
normal persons, as might be the case if family size became more standardized,
a system in which heterozygotes avoided marriage would prevent a decrease
in abnormal gene frequency. There might even be a slow increase due to
fresh mutations, though several thousand generations would pass before the
150
frequency of carriers would be doubled.
Sterilization of heterozygous carriers appears unlikely to have any
substantial impact on reducing deleterious genes. If the program were
compulsory, it would require 1,500 years to reduce the frequency of a particular
recessive gene by half.151  If sterilization is undertaken on a voluntary basis,
the rate of decrease would be much less. Thus, the elimination of a recessive
defect by sterilization is a very slow process and probably of no immediate
149Ibid., p. 28.
150
Ibid.
151Ching Chun Li, Population Genetics, (The University of Chicago Press:
Chicago, 1955), p. 253.
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value in eugenic programs.
C. Voluntary versus Compulsory Screening: Genetic screening raises
other essential policy issues. One crucial and heavily debated issue concerns
the nature of such programs: Should participation in screening programs be
voluntary or be made compulsory? The controversy over this question has
152
turned into a full-fledged debate. At least ten states and the District
of Columbia have enacted screening programs which will either require, or
at the discretion of a doctor or health officer may require, black persons
to undergo tests for sickle-cell anemia. There is little disagreement about
the desirability of such tests if they are voluntary, but when the tests are
made mandatory, the debate becomes vigorous.
The City Councilman who introduced the compulsory sickle-cell anemia
legislation in the District of Columbia defends his position, contending that
"this is a trait and a disease that has been ignored. There is no cure, but
a family knowing the facts would know what counseling or steps to take . .
I don't think we can get at the problem on a voluntary basis. There is too
much apathy."153 On the other side of the debate, there are many persons who
find mandatory programs both unnecessary and counter-productive. A recent
genetics task force of the Institute of Society, Ethics, and the Life Sciences
strongly urged that
152The ten states are: Georgia, Illinois, Indiana, Iowa, Kentucky,
Louisiana, Maryland, Massachusetts, New York and Virginia. At least four
of these states - Maryland, Massachusetts, New York, Virginia - and the
District of Columbia will consider legislation in 1973 to repeal the
compulsory features of their programs.
153Henry S. Robinson, quoted in Victor Cohn, "Disease Publicity Raises
Problems." Washington Post, November 12, 1972, p. A12.
50
genetic screening programs should be conducted on a voluntary
basis . . . . There is currently no public-health justification
for mandatory screening for the prevention of genetic disease.
The conditions being tested for in screening programs are
neither "contagious" nor, for the most part, susceptible to
treatment at present. 154
It is also feared that state enforced screening programs will be the beginning
of greater government intervention into what many consider to be an area for
private decision-making.
When you start talking about compulsory testing, you also
start talking about compulsory genetic counseling. When
you start talking about compulsory genetic counseling, you
start talking about putting the state behind it. Then you
get into all sorts of implications . . . . I'm for voluntary
sickle trait testing, but I believe compulsory genetic
testing sets a bad precedent in our kind of society.155
The possible implications of compulsory counseling might include state-
supported marriage and sterilization laws for genetic purposes, the precedents
for which already exist. In fact, 25 states still retain eugenic sterilization
statutes, 22 of which are compulsory.156 There are also state laws prohibiting
154A report from the Research Group on Ethical, Social and Legal Issues
in Genetic Counseling and Genetic Engineering of the Institute of Society,
Ethics and the Life Sciences, "Ethical and Social Issues in Screening for
Genetic Disease," The New England Journal of Medicine, Vol. 286, May 25, 1972,
pp. 1130-31. In the case of sickle-cell anemia there is no acceptable and
effective treatment at this time. See R.B. Scott, "Urea Therapy in Sickle-
Cell Anemia," The New England Journal of Medicine, 285: 1025-26, nctober 28,
1971.
155Paul McCurdy, Georgetown University, quoted in Victor Cohn, op. cit.,
supra, n. 153.
156William R. Matoush, "Eugenic Sterilization 
- A Scientific Analysis,"
Denver Law Journal, Vol. 46, 1969, p. 633. In recent years, however, these
laws have not been enforced.
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consanguinous marriages, most prohibiting marriage between first cousins or
157
persons more closely related. Might not the same legal rationale which
led to these laws also be used to justify their application to carriers of
deleterious genes?158 While a definitive answer is not possible at this time,
there is some speculation that all such laws might be declared unconstitutional.
159
In Griswold v. Connecticut, the Supreme Court held that the state has no
power to interfere with the use of contraceptives by married couples, such
use being considered one of the rights reserved to the people under the Ninth
Amendment. If one interprets the case broadly, it may be read "to affirm
that the decision by a husband and wife to have children, or not to have
children, or how many children to have, is one in which the state may not
interfere, whether the purpose be to limit the population or to improve it
160
eugenically." Underlying this reasoning are certain assumptions regarding
the "rights" of couples to reproduce.
D. Procreation and Genetic Disease: If procreation is viewed as a
couple's "right," then it should be useful for planning genetic counseling
activities and services to have some feeling for the kinds of reproductive
decisions that couples will make and the reasons for their decisions. Ramsey
157Michael Farrow and Richard Juberg, "Genetics and Laws 'Prohibiting'
Marriage in the United States," Journal of the American Medical Association,
209: 535-538, July 28, 1969.
158In this regard it is interesting to note that Virginia's law also
requires sickle-cell screening for marriage license applicants. Virginia
Code, section 32-112.14
159
381 U.S. 479 (1965).
160Frank P. Grad, "Legislative Responses to the New Biology: Limits and
Possibilities," UCLA Law Review, Vol. 15, February 1968, p. 488.
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finds it "shocking to learn . . . how many parents will accept grave risk of
having defective children rather than remain childless." 161 Unfortunately,
there are only a few empirical studies concerning the tendency toward risk-
taking among couples and the results are somewhat mixed. In his study of 25
couples, Fletcher found that "Given the choice of accepting a genetically
162
defective child or resorting to abortion, . . they would choose the latter."
Another study involving 455 couples found that "on the whole, they took
responsible decisions on the basis of the information. Where the recurrence
risk was high - that is, equal to or greater than 1 in 10 - two-thirds (109
out of 170) were deterred from planning further children."16 3  In his study
at Yale, Hsia reports that only 25 per cent of the couples in a high risk
164
group were deterred by counseling. And in their study of 76 families,
Leonard and his colleagues report that 34 (45 per cent) stated that "They
165
regarded the disease as a reason for curtailing reproduction." Finally,
161 Ramsey, op. cit., supra, n. 89 at 166.
162 Fletcher, op. cit., supra, n. 134 at 53-54.
163
C.O. Carter, K.A. Evans, J.A. Fraser-Roberts and A.R. Buck, "Genetic
Clinic: A Follow-Up," Lancet, Vol. 1, February 6, 1971, p. 281. Both this
and the Fletcher studies may be somewhat biased due to the character of the
sample populations. The majority of the Fletcher sample was middle-class
and has a graduate degree, while the Carter, et. al., sample over-represented
the upper social classes and was probably above average in education.
164
Y.E. Hsia, "Choosing My Children's Genes," Paper presented at the
American Association for the Advancement of Science annual meeting,
Washington, D.C., December 29, 1972.
165
Claire 0. Leonard, Gary A. Chase and Barton Childs, "Genetic Counseling:
A Consumer's View," The New England Journal of Medicine, Vol. 287, August 31,
1972, p. 435. This study focused on parents of children with three types of
genetic diseases: cystic fibrosis, phenylketonuria, and Down's syndrome.
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the results of a follow-up study166 in England of 53 women referred for genetic
counseling in families with Duchenne muscular dystrophy (a sex-linked disease
for which there is no treatment) can be summarized as follows: Of the 41
women at high risk (defined as greater than 1 in 10), 36 decided to have no
further children and two decided upon selective abortion. Only two disregarded
the risks and intentionally became pregnant. Of the five women at medium
risk (1 in 10 to 1 in 20), only one planned to have further children. The
others considered the risks too great. Of the seven women at low risk (less
than 1 in 20) only one was not reassured by the low risks and has avoided
167
pregnancy.
It should be pointed out that in most cases these studies refer to the
impact of genetic counseling on couples' reproductive intentions, not their
observed reproductive behavior. Generally speaking, these data suggest that
counseling can have a significant impact on reproductive attitudes. The
findings regarding actual reproductive behavior are not so encouraginq. In
the largest of the aforementioned studies, Carter and his colleagues report
that of those high-risk couples who stated that they were attitudinally
deterred from having further children, 24 per cent (26 out of 109) had at
least one additional pregnancy. Among the low-risk couples, who also claimed
to be attitudinally deterred, 15 per cent (9 out of 60) had at least one
166A.E.H. Emery, M.S. Watt and E.R. Clack, "The Effects of Genetic
Counselling in Duchenne Muscular Dystrophy," Clinical Genetics, 3:147-150,
1972. The investigators report that all social classes were represented and
that their distribution was similar to that of the general population.
167
Ibid., pp. 148 and 149.
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additional pregnancy. At least in this particular study, there appears
to be a considerable degree of difference between the impact of genetic
counseling on reproductive attitudes and its impact on actual reproductive
behavior. There is an obvious need for more systematic investigation into
the question of risk-taking as well as for determining those factors which
influence such reproductive decisions. James R. Sorenson has identified some
of these factors: "(1) the size of the risk, (2) the severity of the potential
abnormality, (3) the social and private attitudes of the parents toward
abnormality, (4) the economic capacity of the family to endure the burden of
a genetic disease, (5) the genetic health of existing children, and (6) the
169
type of counseling parents receive." But as he points out, there is little
data concerning the specific role that each of these factors (and perhaps
other factors as well) plays in parental decision-making.
There is no consensus, however, that there is, or should be, a "right
to procreation." Ramsey believes that
If the fact situation disclosed by the science of genetics
can prove that a given person cannot be the progenitor of
healthy individuals (or at least not unduly defective
individuals) in the next generations, then such a person's
"right to have children" becomes his duty not to do so, or
to have fewer children than he might want (since he never
had any right to have children simply for his own sake). 170
Thus, Ramsey calls for the development and adoption of an "ethics of genetic
168
Carter, et. al., op. cit., supra, n. 163 at 283.
169James R. Sorenson, "Social Aspects of Applied Human Genetics," Social
Science Frontiers, 1971, No. 3, Copyright (c) 1971 by Russell Sage Foundation,
New York, p. 13.
170Ramsey, op. cit., supra, n. 87 at 35.
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duty," whereby couples act responsibly and morally in order to prevent the
birth of a defective child. Joseph Fletcher suggests that a more appropriate
guideline for developing policy is "needs." He explains that
Needs are the moral stabilizers, not rights . . .. If human
rights conflict with human needs, let needs prevail. If
medical care can use genetic controls preventively to
protect people from disease or deformity, or to ameliorate
such things, then let so-called "rights" to be born step
aside.
Rights are nothing but a formal recognition by society of
certain human needs, and as needs change with changing
conditions so rights should change too. The right to
conceive and bear children has to stop short of knowingly
making crippled15 ildren - and genetics gives us that
knowledge
To what extent the state should be the agent for balancing the genetic
"rights" and "needs" of its people is a question that society may soon have
to face. There may be a fine line between a particular genetic defect being
reason for a couple to refrain from procreation and its being reason for
compulsory restrictions on the part of the state.
E. Target Populations: The nature of the program also raises questions
concerning the populations toward which such programs should be targeted.
The programs aimed at sickle-cell anemia clearly demonstrate the problems
involved. These programs, and their enacting legislation, represent the
nation's first genetic effort directed at a particular race.172 While many
other groups experience a high incidence of genetic disease, e.g. the Ashknazi
171
Joseph Fletcher, "Ethical Aspects of Genetic Conrols: Designed
Genetic Changes in Man," The New England Journal of Medicine, Vol. 285,
September 30, 1972, p. 782.
17 2Sickle-cell anemia, with a frequency of 1 in 400, is the most common
genetic disease in the black population. The incidence among the white
population is much smaller. See Victor Cohn, "Disease's Effects Often
Exaggerated," Washington Post, November 13, 1972, p. A8.
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Jews and Tay-Sachs disease, and those of Mediterranian ancestry and Cooley's
Anemia, none has been singled out for compulsory testing. The problem with
isolating a specific ethnic group is that it might be interpreted as a
racist gesture. Such has been the case with sickle-cell anemia, with some
comparing it to the "racist eugenics legislation that led to the final
,,173
solution in Nazi Germany," and others viewing it, when combined with some
174forms of genetic counseling, as "white genocide." Whether or not these
criticisms are valid, they are one reason for the growing opposition among
blacks to sickle-cell programs. And yet, without their involvement and
cooperation it is unlikely that such programs can accomplish their aims.
There is also criticism of laws such as those in Virginia, which
require the screening of persons in correctional institutions and state
mental hospitals. Some question the intent of such laws, maintaining that
there is
no valid reason why prisoners and mental patients should
be tested . . . the potential for mischief is great . .
scientific knowledge has in the past been perverted to
fulfill social ends, and there is, unfortunately, nothing
S. . which would lead one to believe there is no basis
for alarm.175
173James E. Bowman, Director of Laboratories, University of Chicago,
quoted in Victor Cohn, op. cit., supra, n. 153.
174
Victor Cohn, "Sickle-Cell Project Outlined," Washington Post, July 21,
1972, p. A15. A recent study reports a direct "relationship between fears
of racial genocide and the use of family planning methods." The investigators
note the depth and source of this fear, writing that Negroes are "responding
to a long history of every possible type of oppression which has been
perpetrated against blacks. The resistance to family planning and to family
planning agencies run by whites is merely a symptom of the deep sense of
historical and life-long estrangement." William Darity and Castellano Turner,
"Family Planning, Race Consciousness and the Fear of Race Genocide," The
American Journal of Public Health, Vol. 62, November 1972, pp. 1458-59.
175Bowman, quoted in Victor Cohn, op. cit., supra, n. 153.
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Another concern for screening legislation is the age at which persons should
be screened. For example, the District of Columbia requires that "Each child
admitted to a public school, either kindergarten or the first grade as the
case may be, shall have been tested for sickle-cell anemia." 176 There are
many, however, who believe that testing at such an early age is of dubious
value and probably undesirable. They argue that these children "are too young
to fully understand the implications of being a trait carrier, could suffer
from the stigma, and may forget all about it by the time they are likely to
177
be considering marriage and child-bearing." Much more data needs to be
collected regarding the "best time" at which to initiate such testing.
F. Program Design and Management: Another broad policy concern is the
implementation and administration of screening programs. It is essential
that screening programs be designed for the purpose of attaining one or more
predetermined goals. Establishing clearly defined goals will help to avoid
circumstances which might be costly in both scientific and human terms. A
recent report suggests that the most important goals of a screening program
are those that
either contribute to improving the health of persons who
suffer from genetic disorders, or allow carriers for a given
variant gene to make informed choices regarding reproduction,
or move toward alleviating the anxieties of families and
communities faced with the prospect of serious genetic disease.178
176Regulation No. 72-9, section 2 (May 5, 1972).
177B.J. Culliton, "Sickle-Cell Anemia: National Program Raises Problems
As Well As Hopes," Science, Vol. 178, October 20, 1972, p. 284. Also,
E. Beutler, D.R. Boggs, P. Heller, A. Maurer, A.G. Motulsky, and T.W. Sheehy,
"Hazards of Indiscriminate Screening for Sickling," The New England Journal of
Medicine, 285: 1485-86, December 23, 1971.
178Institute of Society, Ethics and the Life Sciences, op. cit., supra,
n. 154 at 1129.
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Another reason for establishing goals is to assist in program evaluation. If
screening programs are to compete successfully with other programs for resource
allocation, it will be necessary to provide "proof" of their effectiveness in
order to justify public support. Identifiable goals are clearly needed for
such evaluation. "Evaluation cannot exist in a vacuum. One must always ask
evaluation 'of what.' Every action, every program has some value for some
179
purpose." Thus, an important task for program planners and administrators
will be to develop appropriate measures and techniques for evaluating their
180
efforts.
The design and operation of screening programs raises other important
considerations for policy-makers. One general observation concerns the
relationship between public programs such as genetic screening and the commu-
nities to be served. Citizen pressure is becoming more influential in
determining what services the community will receive. Suchman writes that
Once sufficient evidence has accumulated to indicate the
potential benefits of a program, the public is likely to
demand the program without waiting for conclusive proof.
The greater the need, the stronger the pressure to put the
program into operation as soon as it begins to look
successful.
Thus, "popular causes" spring up which bring pressure upon
the program administrator to satisfy public demand regardless
of professional judgment or evaluation findings.181
179Edward A. Suchman, Evaluative Research: Principles and Practice in
Public Service and Social Action Programs, (Russell Sage Foundation: New York,
1967), pp. 37-38.
180For a relevant discussion of the needs and problems of program
evaluation, see Suchman, Ibid., especially chapters 6-8; Aaron Wildavsky,
"The Self-Evaluating Organization," Public Administration Review, 32:509-520,September/October 1972; and Thomas A. Morehouse, "Program Evaluation: Social
Research Versus Public Policy," Ibid., 32:868-874, November/December 1972.
181
Suchman, op. cit., supra, n. 179 at 153 and 152.
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The difficulties involved are illustrated by the history of PKU legislation,
in which "a small group of determined and highly motivated parents of mentally
retarded children, together with a few equally dedicated physicians, needed
less than three years to persuade forty-one states to pass laws requiring the
182
testing of newborn children for phenylketonuria . . . ." This effort has
been characterized as "a simplified and incomplete understanding of the
objective situation, a singleminded campaign which trumpeted success and ignored
failures, and most of all a failure to consider the harm that might be done
183
by seeking to do good." The result has been a "poor piece of legislation,
184
one with noble aims, but based upon unwarranted medical assumptions." If
the circumstances surrounding the evolution of PKU legislation are studied
carefully, it may be possible to avoid similar pitfalls in planning future
185
screening programs.
G. Screening Tests: Extra care must be taken to develop testing procedures
that will be accurate and subject to a minimum latitude of interpretation. A
problem which might develop as a result of unreliable testing methods is that
a "high proportion of false negatives or false positives not only will cast
suspicion and discredit on the method, . but may result in professional
182 Bessman and Swazey, op. cit., supra, n. 47 at 49.
183 Ibid., p. 50.
184American Academy of Pediatrics, "New Child Health Legislative Bills
Proposed - Academy Subcommittee Issues Guidelines," quoted in Bessman and
Swazey, Ibid., P. 72.
185History may already be repeating itself. There are cries that a new
kind of "sickle-cell crisis," one due to hastely drawn and poorly-planned
sickle-cell legislation, is occurring. See Cohn, op. cit., supra, n. 153
at Al.
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186
malpractice charges ... ." The case of PKU illustrates this problem as
well as more serious consequences.
Laboratory tests do not detect PKU but rather high blood
phenylalanine levels, which can have causes other than PKU.
Furthermore, the tests suitable for the mass screening
required by law are subject to misinterpretation and error.
The tests are not accurate; they miss a number of cases of PKU
and yield false positive reactions in an even greater number.
Given a positive test, the physician will very probably put
the child on a low phenylalanine diet . . . But a child who
does not have PKU is actively endangered by the diet and can
suffer physical deterioration at the least; a number of
children have died from being treated for PKU, and it is
likely that they did not have the disease.187
While it may be claimed that the physician is still able to decide the
appropriate course of treatment for an infant, the fact that such legislation
is a matter of public policy exerts a "powerful stimulus to prescribe in
accordance with the cultural mores"188 and, in the case of PKU, has resulted
in the use of an unproven treatment. Reliable testing procedures, therefore,
are necessary both to assure proper treatment and to gain the confidence and
cooperation of the community.
H. Screening Services and Delivery: There is also the question of what
services should be included in the designing of screening programs. At a
minimum, such services should include follow-up diagnosis, treatment and
186
Irving Ladimer, "Legal Consideration in Screening, Treatment,
Counseling and Research in Sickle Cell Disease," Paper presented at a
Symposium on Sickle Cell Disease, New York, November 19, 1971, pp. 7-8.
187Bessman and Swazey, op. cit., supra, n. 47 at 50-51.
188Joseph D. Cooper, "The Role of Government Legislation in Management
of Problems in Medicine," in Anderson and Swaiman (eds.), op. cit., supra,
n. 46 at 170. Bessman and Swazey report that there have been at least
"half a dozen malpractice suits involving PKU." op. cit., supra, n. 47 at 72.
61
genetic counseling. Some geneticists contend that
It is probably unjustified on ethical grounds to mount
large-scale screening programs for disease or carrier
detection in conditions where the patient and carriers
cannot be offered specific effective medical therapeutic
alternatives, including intrauterine diagnosis and
abortion.18 9
This reference to abortion raises sensitive policy questions, including
whether or not public funds should be used to provide abortion services. If
society's resources are expended in order to provide families with information
that is required for intelligent reproductive decision-making, can it then
deny them the option to implement their decision, an abortion being one option
they might choose?
Genetic counseling also has an important role to play in screening
programs. First, it can provide couples with the basic genetic information
required to make informed and intelligent decisions about subsequent
pregnancies. And second, it provides the follow-up support needed to help
those couples implement their decisions.
In providing information to couples, the genetic counselor will be able
to explain the source and meaning of a particular defect and, after appropriate
testing and analysis, inform them of the risk of its occurrence or recurrence.
The lack of such information might lead to poor decision-making in either of
two directions. Some couples might have additional children when the
probability is high that their future offspring will be adversely affected.
Or, conversely, couples with conditions in which the risk is very low may
189
Robert F. Murray, Jr., "Problems Behind the Promise: Ethical Issues
in Mass Genetic Screening," The Hastings Center Report, Vol. 2, April 1972,
p. 13.
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have no further children as a consequence of unreasonable fear. A recent
study of families with genetically-ill children found that
regardless of socio-economic class, birth order of the
chronically ill child, religion, burden of care, and the
heriditary nature of the condition, families continue to
have children, whether purposefully or unplanned as do the
parents of normal children. There is a strong indication,
however, that this would not be the case if parents were
aware of the risk involved in the transmission of genetic
defects and if this information were coupled with knowledge
of effective techniques to prevent pregnancy.190
Thus, the proper transmission of genetic information to couples might help
them in planning their future families.
On a second level, counseling is needed to help couples adjust to and
implement their reproductive decisions. A few examples drawn from case
studies provide some insight into the various demands that would call for
follow-up counseling. Fletcher studied the period of time following
amniocentesis and found
the parents in considerable anxiety, and whatever problems
existed in their marriage or family relationships were
exacerbated . . . . If a marriage is troubled, the strains
will most likely break forth in this period, testing to the
limits the capacity of the couple to face their problem and
make plans . . . . Counselors should be particularly attentive
to the deeper personal problems which emerge in this period. 191
Fletcher describes existing counseling centers as poorly set-up to deal with
these problems, noting that perhaps "one in twenty-five centers would be
sensitive to marital problems and fewer than that would have the means to
help people."192 He also found couples in "need for support and counseling
190 Harry Sultz, Edward Schlesinger and Joseph Feldman, "An Epidemiologic
Justification for Genetic Counseling in Family Planning," The American Journal
of Public Health, Vol. 62, November 1972, p. 1492.
191 Fletcher, op. cit., supra, n. 134 at 56.
192
Interview with John Fletcher, supra, n. 114.
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at the time of therapeutic abortion and the deep depression suffered at the
time." 193 Unfortunately, he notes that abortion counseling facilities are
less than adequate for the task.
Counseling might also be required to follow up on the initial diagnostic
tests. It is important to consider the total health needs of the patient and,
to use the case of PKU, neglect of such needs regarding the dietary problems
might result in more serious physical and emotional problems.
When treatment of a child involves restrictions in diet,
it has broad implications for the entire family. How
the parents feel about food, how much they use food as a
weapon in the parent-child relationship, and how the other
children in the home react, can mean the success or failure
of the dietary regime. Consideration of the child as a
member of a family that has many other responsibilities
requires that medicinal and dietary care be obtainable
without undue drain on family resources. 194
There is need to assure, then, that any intervention into the genetic
decision-making process will not be more injurious to the individual and/or
his family than if such intervention had not occurred.
Counseling support might also help couples overcome the severe guilt
feelings which often accompany the birth of an affected child. In the case
of hemophilia, for example
there is a need to deal with the emotional upset that
occurs - the shock at the discovery, the guilt and the
self-blame which comes from the inevitable feeling that
parents are somehow responsible for causing the disorder
and the fears as to what hemophilia entails.
193
Fletcher, op. cit., supra, n. 134 at 51.
194Recommended Guidelines for PKU Programs for the Newborn, (U.S.
Department of Health, Education and Welfare, Health Services and Mental
Health Administration, 1971), Public Health Service Publication No. 2160,
p. 9.
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Helping the family through the upset is, of course,
important in its own right, but it is also necessary for
treatment purposes. Until the emotional problems are
handled, it is very likely that the therapeutic efforts
which require education of the parents about the reality
of hemophilia will be hampered.195
Family follow-ups and counseling, therefore, might provide both the parents
and the affected child with more effective genetic guidance.
A commitment to create such counseling services also entails the
responsibility to ensure that the services reach prospective consumers. In
his study of 250 counseling units, Sorenson found 25 per cent located in a
hospital setting. He contends that
Hospital based medical genetics will probably increase
significantly as the impact of the various intrauterine
diagnostic procedures become more accepted . . . . Today,
with various forms of heterozygosity detection possible,
as well as amniocentesis, there is an increasing need for
the delivery of medical genetics to be associated with the
facilities of a hospital and laboratory.196
This setting, according to Sorenson, will not only permit the maintenance of
adequate facilities, but will most likely increase "the proportion of lower
195
Lee Salk, M. Hilgartner and B. Granick, "The Psycho-Social Impact of
Hemophilia on the Patient and His Family," Social Science and Medicine, Vol. 6,
August 1972, p. 503. In the same article (p. 496), the investigators report
that in "14 of the 25 cases, there appears to be a clear-cut deleterious
impact, e.g. contributing to the breakup of the marriage or most leading to
a psychological withdrawal by the husband from family relationships." For
further evidence highlighting the presence and impact of parental guilt, see
David G. Langsley, "Psychology of a Doomed Family," American Journal of
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pp. 14 and 15.
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socio-economic groups receiving counseling."
Consideration should also be given to the nature of the delivery mechanism.
A prime requirement for any mechanism we devise to deliver
service is that it be sufficiently flexible so that we can
individualize the service package to fit in not only with
abilities and peculiarities of the agents who are dispensing
service but also with the individual differences of the
consumers who receive them, and the communities and settings
in which such services are provided and utilized. 198
The importance of this point can be sufficiently demonstrated by the recent
attempts of the National Institutes of Health to promote an employee sickle-
cell testing campaign. The program was cancelled; one of the major reasons
given for this was that it was "not organized by blacks with black feelings
in mind." 199 The Institute of Society, Ethics and the Life Sciences has
recommended that "From the outset program planners should involve the
communities affected by screening in formulating program design and objectives,
in administering the actual operations of the program, and in reviewing
200
results."
I. Screening Facilities and Organization: The provision of adequate and
functional diagnostic facilities must also receive high priority from program
planners. For maximum quality control and personnel expertise, testing should
probably be done in regionally centralized laboratories so that costs can be
minimized and the training of qualified personnel more easily accomplished.
197Sorenson, op. cit., supra, n. 169.
198 Rudolph Hormuth, "Organization of Community Services in Phenylketonuria,"
in Anderson and Swaiman (eds.), op. cit., supra, n. 46 at 165.
199Victor Cohn, "Black Health Care Laq Cited," Washington Post, November 15,
1972, p. A12.
20 0O. cit., supra, n. 154 at 1130.
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Because "biochemical assays necessitate facilities that often are well
beyond the means of the average clinical laboratory, [it] simply is not
feasible for one laboratory to perform all of the tests now possible . .
Thus,
A screening program should be carried out in conjunction
with a facility large enough to handle a volume of samples
sufficient to detect several positive cases per year to
assure experience in laboratory diagnosis. Efficiency is
materially increased when a single central laboratory is
utilized. The development of a system of quality control
on a statewide or regional basis should be considered to
insure a high degree of reliability of results.202
Similar consequences to those which resulted from the impact of public
pressure on the evolution of PKU legislation (supra, pp. 59-60) might also
occur during management of diagnostic facilities and the provision of follow-
up services. Past experience with establishing abortion facilities to meet
expanding demands203 and the difficulties which appear to be emerging in the
201
"Geneticists Press for Regionalization," Laboratory Management,
Vol. 10, October 1972, p. 25.
202Recommended Guidelines for PKU Programs for the Newborn, pp. cit.,
supra, n. 194 at 4. Such a network has been established by the National
Genetics Foundation, Inc. Each of their 45 centers in the United States and
Canada is staffed and equipped to perform the biochemical and chromosomal
analyses necessary to diagnose the most common genetic diseases. In addition,
some of the centers have the specialized personnel and facilities required
for diagnosis of one or more rare genetic defects. All of the centers are
staffed to provide genetic counseling and follow-up to any diagnosis. See
their brochure "Genetic Counseling and Treatment Network," (National Genetics
Foundation, Inc., 250 West 57th Street, New York 10019).
203Neubardt and Schulman discuss the problems which resulted in New York
following the changes in its abortion law and conclude that "Abortion has
exposed in rather vivid fashion the weaknesses of our medical institutions."
op. cit., supra, n. 68 at 105-106.
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development of hospital cardiac programs,204 demonstrate the problems
confronting program planners caught up in a cross-current of public pressure.
The problems may already be emerging in the newly-enacted sickle-cell screening
programs. Virginia, like a number of other states, hurried to join the
bandwagon of states with sickle-cell testing programs. However, Virginia's
Department of Health reports that "Sufficient funds have not been appropriated
for recruiting or hiring the appropriate number of genetic counselors. . .
Until additional funds are appropriated, we are simply unable to meet all of
205
the responsibilities placed upon us by the new legislation." The consequences
which result, and which merit emphasis, are not only that the necessary
facilities and services will not be provided, but that a "confidence gap" is
created between those designated to provide and perform the services and those
who are to receive them. Such a situation obviously benefits no one and, in
the final analysis, is probably counterproductive.
J. Screening Costs: There is also a need to consider the cost of
screening and counseling services. The use of various diaqnostic tests and
extensive laboratory work can be quite expensive (for example, a typical
examination with ultrasound of a potentially abnormal pregnancy can cost as
204The Inter-Society Commission for Heart Disease Resources reported
that hospitals are under new public pressure to enlarge their cardiac
programs. The Commission warned that "With the introduction of new techniques
for coronary-artery surgery hospitals are again being stimulated to expand
their surgical programs and there is evidence we may again see a proliferation
of poorly planned units with costly duplications of facilities and suboptimal
care." See "Hospitals Warned on Heart Surgery," Washington Post, October 16,
1972, p. A15.
205Patricia Hunt, Director, Bureau of Child Health, in a letter to this
author, October 6, 1972.
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high as fifty dollars). Systematic study is needed of the costs involved
in providing genetic services to the population and the extent to which
such services are not used because of a family's financial circumstances.
Also important is the role of private health insurance in helping families
absorb the costs of genetic services. At this time,
No insurance company . . . recognizes the concept of
preventive medicine. The fetus is not recognized as
a patient. Cytogenetics is not, for the most part,
recognized. The insurance situation seems particularly
outrageous when one stops to consider that preventive
medicine will be the mainstay of health care in the
next century.206
As the availability and demand for genetic services increase, the question
of costs will become an increasingly important matter.
K. Screening and Genetic Information: The collection and dispersion
of genetic information acquired through screening programs also raises
important policy questions. As more and more genetic information about
individuals and their families is accumulated, how should it be used? What
protection should be guaranteed to the individual to whom such information
refers? Those who establish data-gathering systems need to be aware of the
possible abuse of the information which they possess.
The management of screening programs carries with it two inherent
potential sources of abuse. First, in a large-scale screening program
206Carlo Valenti, quoted in Laboratory Management, Vol. 10, October
1972, p. 23. Geneticist Valenti reported that Blue Cross/Blue Shield has
"agreed to partially cover the cost of diagnosis depending upon the type
of policy held by the patient. However, the reimbursement schedule which
they have offered is still less than adequate: $25-40 for a chromosome
analysis and $15-25 for a buccal smear. These figures compare with hospital
charges of $100 for a diagnosis based upon leukocyte cultures, $250 for
a diagnosis based upon amniotic fibroblast cells, and t40 for a buccal
smear."
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the responsibility for the quality and quantity of care that a patient
receives rests with a team of medical experts rather than in the context of
of the traditional doctor-patient relationship. Thus, both the medical and
ethical responsibilities to the patient are more diffused and consequently
more difficult to fix. Experience with PKU screening illustrates this point.
Not only are records of tests filed in several different
places in the state health department, but the entire
preventive medicine apparatus of the state, including
psychology, nursing, statistics, social services, nutrition,
and education, is alerted to the condition. In this
process, information which could seriously affect an
individual for life is passed about among nonprofessional,
nonmedical personnel who have no legal or moral responsibility
to the individual. 207
The second potential source of abuse arises from the use of computerized
data-gathering techniques. A vast network of screening programs not only
calls for the collection of large amounts of data, but also requires that
such data be rapidly and efficiently stored, retrieved and transmitted
between diagnostic centers. The ability of the computer to meet these demands
makes it an ideal tool for such data management. The problems posed by the
use of computers are not new. They simply change the economics and nature of
processing information in ways that could result in the abuse of civil
liberties. Questions regarding what data is to be collected, for what
purposes, to whom it will be made available, and what mechanisms will exist
for individuals to obtain and contest such data are all matters for public
policy. A recent report of the National Research Council's Computer Science
and Engineering Board describes the challenge to policy-makers.
207Bessman and Swazey, op. cit., supra, n. 47 at 73.
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Our task is to see what appropriate safeguards for the
individual's rights to privacy, confidentiality, and
due process are embedded in every major record system
in the nation, particularly the computerizing systems
that promise to be the setting for most important
organizational uses of information affecting individuals
in the coming decade.208
The risks involved in the collection of confidential information from
any part of the population are accepted by society because of the presumed
benefits of using this information. In the case of genetics, for example,
the identification of heterozygous carriers would be of great value in
estimating the gene frequency among different population. From this
information one could calculate the number of individuals who are likely to
be affected within the particular population. Thus, better planning for
and control of genetic disease are potential benefits to be derived from
screening programs. There is a need, therefore, to strike a balance between
the community's requirement for information and its subsequent use and the
individual's rights of privacy.
L. The Misuse of Information: In developing an appropriate information
policy, one should bear in mind the kinds of abuses that might affect a
"defective" individual. One such abuse is the possibility of encumbering
him with a lifelong public stigma. A diagnostic medical label can destroy
or distort relationships within a family and can close access to many of the
normal channels and outlets usually open to people. Such influence can
result in two ways: first, through affecting an individual's attitudes, his
208Quoted in Gerald S. Schatz, "Computers and Privacy: Continuing
Questions of Civil Liberties," News Report, Vol. 22, December 1972, p. 5.
(News Report is a monthly publication of the National Academy of Sciences).
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image of himself, his self-confidence and, therefore, his involvement in
an activity; or second, by identifying a person in such a way so that he
is systematically discriminated against. Past experience with genetic diseases
illustrates this point clearly. Persons with Huntington's chorea, a disease
characterized by progressive mental deterioration, will probably manifest
signs of the disease by age 35, but may not have symptoms until a much later
age. Until that time they are quite capable of functioning normally.
However, the stigma which is often associated with a family with a history
of the disease has resulted in "great secrecy within the family because of
the fear of social, economic, or legal penalties should the knowledge be
made public."209
The case of sickle-cell anemia illustrates the problems incurred by the
innocent carrier of the disease. The major problem is confusing the person
who has the disease with the person carrying the trait, but not the disease
symptoms. A recent report expressed concern about the
dangers of societal misinterpretation of similar conditions
and the possibility of widespread and undesirable labeling
of individuals on a genetic basis. For instance, the lay
public may incorrectly conclude that persons with sickle
trait are seriously handicapped in their ability to
function effectively in society . . . Extreme caution
should therefore be exercised before stm that lend
themselves to stigmatization are taken.
A consequence of such stigmatization is that "much unnecessary anxiety on
the part of parents and trait carriers and psychologic harm occurs when some
209John Whittier, Audrey Heimler and Charles Korenyi, "The Psychiatrist
and Huntington's Disease (Chorea)," American Journal of Psychiatry, Vol. 128,
June 1972, p. 1550.
210Institute of Society, Ethics and the Life Sciences, op. cit., supra,
n. 154 at 1132.
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persons are identified as carriers of sickle-cell trait without an
understanding of the harmlessness of their trait."211  Individuals might
come to be regarded as physically weaker or less fit. An example drawn from
experience with another disease may help to illustrate the possible harm.
Dr. Nicholas Hobbs, director of the staff for a five-agency federal study of
labeling, has reported "growing evidence that for a child to be labeled
anything - whether the label is 'mentally retarded' or 'gifted' - influences
212
what social system he gets into and shapes his whole future." Hobbs
cites the example of a young child who was found to have a heart murmur. He
was treated differently by his parents, "sheltered and not allowed to play
with other children." Five years later doctors found the child's heart
perfectly good, but by then "he had already developed a picture of himself
as having heart disease and had taken on a restricted life-style that may
never fully reverse." Great care must be taken, therefore, to avoid
"overprotecting" carriers when it might later result in their adopting
unnecessary and restrictive life-styles.
Another problem has been the denial to some sickle-trait carriers of
employment opportunities or life and health insurance. For example there
are reports that an airline stewardess was grounded after the airline
discovered she carried the trait.213 Also, insurance companies "have been
211 Beutler, et. al., op. cit., supra, n. 177 at 1486.
212Quoted in Suzanne Dean, "Study Probes Labeling of Children as Retarded,"
Washington Post, September 6, 1972, p. A8.
213Rudolph Jackson, Coordinator, National Institutes of Health sickle-
cell disease program, quoted in B.J. Culliton, "Sickle Cell Anemia: The
Route from Obscurity to Prominence," Science, Vol. 178, October 13, 1972,
p. 141.
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changing or raising the premiums or dropping insurance on persons with the
214
trait . . ." Thus, "sickle-cell testing has shown up in employment
records, in insurance company records, and is becoming more and more abused
215
by people who do not understand the nature of the disease." While certain
carriers of the sickle trait can experience some problems where the oxygen
supply is diminished, most carriers will never have any problems and there
is "no evidence that trait carriers have a higher risk of disease or a shorter
216
than normal life-span." This stigmatization of sickle-cell carriers has
"created emotional resistance among many persons to sickle cell screening and
217
genetic counseling . ." and consequently, the effectiveness of such
programs has been greatly impaired.
The XYY chromosome abnormality presents yet another problem associated
with stigmatization. This sex anomaly occurs in males with two Y chromosomes
and one X chromosome (the normal chromosome complement for males is one of
both X and Y chromosomes). The controversy which surrounds this aberration
concerns the extent to which its presence predisposes an individual to engage
in antisocial and violent behavior. A review of the literature indicates that
the controversy is far from resolved. On the one hand, there are studies
214Rudolph Jackson, quoted in "Bias Against Sickle Trait Victims Probed,"
Washington Post, November 14, 1972, p. A6. Some insurance firms have been
reported to charge trait carriers as much as "150 per cent of the usual
premium .. ." Joseph Christian, quoted in Culliton, op. cit., supra, n. 213
at 142.
215Mona Blake, School Board, Fairfax County, Virginia, quoted in "Sickle
Cell Examination is Opposed," Washington Post, November 1, 1972, p. B9.
216Christian, op. cit., supra, n. 213.
217Cohn, op. cit., supra, n. 153 at Al.
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which suggest a correlation between the XYY abnormality and certain types
of aberrant behavior, with one concluding that "the additional Y-chromosome
genetically predisposes the 47, XYY male to the development of a psychopathic
218
personality and to consequent aberrant behaviors and antisocial conduct."
There is equally persuasive evidence, however, which suggests that there is
no strong correlation between the presence of the XYY chromosome complement
and a particular type of behavior. Two researchers recently claimed that the
suggestion that "XYY males are uncontrollably aggressive psychopaths appears
to be nothing more than a myth promoted by the mass media."219  In addition
to the mixed findings suggested by these studies, there are also questions
regarding the methodological and conceptual approaches employed in the
220
investigations. In light of this continuing debate, therefore, any attempt
to develop policy which seeks to respond to the needs of individuals with the
XYY anomaly would be premature.221 The present state of knowledge does not
218
W.M. Court Brown, "Males with an XYY Sex Chromosome Complement,"
Journal of Medical Genetics, Vol. 5, 1968, pp. 348-49. Also see
Lytt Gardner and Richard Neu, "Evidence Linking an Extra Y Chromosome
to Sociopathic Behavior," Archives of General Psychiatry, 26: 220-222,
March 1972.
219 219Seymour Kessler and Rudolf H. Moos, "XYY Chromosome: Premature
Conclusions," Science, Vol. 165, August 1, 1969, p. 442. Also see S. Wiener
and G. Sutherland, "A Normal XYY Man," Lancet, 2:1352, December 21, 1968.
220 Saleem A. Shah (ed.), Report on the XYY Chromosome Abnormality,
(National Institute of Mental Health: U.S. Government Printing Office, 1970),
Public Health Service Publication No. 2103, pp. 23-27.
221
The questions for policy consideration might include how much effort
should be directed toward rehabilitating criminals if the underlying basis
for their abnormal behavior is genetically determined. Or, how should the
XYY individual be dealt with both prior to and following the commission of
a crime? Since the XYY chromosomal abnormality can be detected in utero by
amniocentesis, does society have a right to intervene into the reproductive
decision of couples found to have conceived an XYY child?
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permit any definitive statement regarding the possible link between the XYY
complement and certain types of behavioral pathology. This lack of consensus
highlights the danger "that incomplete or inadequate understanding of the
phenomena might possibly become embedded into public policy or legislative
222
enactments." Thus, there is a need for more systematic data collection and
research into this problem, and others like it, in order to provide the necessary
information from which policy decisions can be made. While such research
itself creates problems regarding the confidentiality of data and individual
privacy, the problem of stigmatization is apparently an immediate one. A
223
recent investiqation concluded that XYY men had been falsely stigmatized
and it is not unreasonable to assume that such information, when improperly
understood, might affect a man's opportunities for gaining employment or
obtaining parole, or prejudice his judicial proceedings.224 Furthermore,
presumptions that a person's chromosome pattern clearly
disposes him toward aggressive and antisocial behavior
could lead to further stigmatization of that individual.
Responses from others interacting with him might be of
222Saleem A. Shah, "Recent Developments in Human Genetics and Their
Implications for Problems of Social Deviance," in Daniel Bergsma (ed.),
Advances in Human Genetics and Their Impact on Society, (Birth Defects:
Original Article Series, Vol. 8: The National Foundation - March of Dimes,
July 1972), p. 79.
223
G.R. Clark, M.A. Telfer, D. Bajer and M. Rosen, "Sex Chromosomes,
Crime and Psychosis," American Journal of Psychiatry, 126: 1659-63, 1970.
224Recently, a public-interest group threatened a law suit regarding
a study inquiring into the frequency of XYY males in a population of children.
The group felt it an invasion of privacy to get information about an individual
that might guide his future treatment. They took the view that the law
might use this information in some way that would adversely affect the
individual. For example, if it was known that an individual was an XYY,
there might be a greater tendency to judge him guilty if arrested by police.
See Robert Cooke, quoted in Maureen Harris (ed.), op. cit., supra, n. 105
at 82.
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a form that would tend to promote aggressive behavior,
thereby making a possible uglrranted assumption become
a self-fulfilling prophecy.
Care must be taken, therefore, to guard against such abuses.
M. Safeguarding Research Data: As suggested earlier, research into
the XYY problem will create its own difficulties. It is important, then, that
the requirements of rigorous scientific research be balanced with the proper
respect for and protection of the rights and welfare of the subjects under
study. The proper protection of the rights of research subjects requires
policy that will safeguard confidential records and protect access to such
information. Unfortunately, only eleven states have statutes that recognize
226
the confidentiality of general research information of a public health nature.
Investigators thus face serious difficulties in protecting such information
from court subpoenas. Even when such statutes are in operation, however, they
are often "overly broad in regard to the possible range of material considered
confidential within the statutes, and thus the researchers and even more
importantly the subject may be misled in relying on a statute that might be
227
given a narrow judicial construction." It would seem to be an appropriate
role of the legislature to formulate more discriminatory models for safe-
guarding the confidential nature of research data. The XYY anomaly, as well
as experience with other genetic abnormalities, illustrates the potential
problems of data management in large-scale screening programs.
225
Shah (ed.), op. cit., supra, n. 220 at 9.
226Ralph K. Schwitzgebel, "Confidentiality of Research Information in
Public Health Studies," Harvard Legal Commentary, Vol. 6, 1969, p. 192.
227
Ibid., p. 196.
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N. Public Education: Much of the stigmatization cited above can be
lessened, and perhaps to a great extent avoided, if the public can be educated
about the nature and consequences of genetic disease. In the case of sickle-
cell disease, the issue is not merely identifying trait carriers, but giving
those individuals and society better information about what being a trait
carrier means. An educated public can thus be a means of "reducing the
potential risk that those identified as genetically variant will be stigmatized
,228
or ostracized socially."228 So far, efforts in this direction have not been
very successful. The excessive pessimism and hostility among blacks toward
genetic screening programs has been attributed to the "large amounts of
'unfortunate sensationalism' and badly informed 'scare campaigns' in TV and
229
newspapers." Clearly, a more carefully constructed and broad-based
educational campaign should accompany genetic screening.
Education, however, has other important functions to perform. Studies
indicate that most people are unaware of the opportunities for genetic services,
with persons of the lower socio-economic classes relying "primarily on family
and friends for information, [which] means not only that they are not likely
to be as informed as others, but that there is an increased chance that they
230
will in fact receive incomplete and often erroneous health information."
Thus, an important task will be to make people aware of available medical
opportunities. Education is also necessary if persons are to be able to make
228 Institute of Society, Ethics, and the Life Sciences, op. cit., supra,
n. 154 at 1130.
229
Cohn, op. cit., supra, n. 153.
230Sorenson, op. cit., supra, n. 196 at 7-8.
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intelligent decisions regarding their future medical and genetic status.
A survey of PKU parents demonstrates the educational challenge ahead. The
survey was designed to find out how much such parents knew about their
circumstances; the results were not very encouraging.
1. 61% did not know the disorder was inherited;
2. 58% did not understand the importance of early diagnosis;
3. 56% said that they had never discussed the condition with
a professional source;
4. 56% did not know that the condition can be treated with a
special diet.231
If genetic screening programs are to be effective in ameliorating the effects
of genetic disease, an educated public is essential.
IV. Genetic Counseling
Genetic counseling is one of the most important means for transforming
the results of medical and genetic's research into measures designed to provide
immediate and practical aid to individuals. The emphasis of the following
discussion will be on the training requirements for genetic counseling, the
possible roles that genetic counselors might assume in performing their
counseling services, doctor-patient communication, and the responsibilities
of the genetic counselor to his patients and society, particularly with respect
to the information to which he has access.
A. Training Requirements: Today there are about 200 genetic counseling
units in the United States. With the increasing awareness of the need for
counseling, the number of these units should proliferate. The services offered
by the units, however, will only be as good as the counseling personnel which
231Lloyd Kramer and Benjamin White, "A Survey of Families and Relatives
of Proven Phenylketonuria (PKU) Patients in Maryland," Paper presented at
92nd Annual Meeting, American Public Health Association, 1964.
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provide them.
What appears to be developing . . . is a rapidly expanding
knowledge base permitting increasingly refined prediction
and control of genetic and chromosomal problems, but no
concomitant professional or organizational locus of training,
socialization and control. What this means is that genetic
counseling as currently practiced exhibits considerable
diversity. With no singular professional training experience,
counselors rely largely on their individual medical
backgrounds, local institutional constraints, as well as
the specific demands placed on h m in the counseling
session to shape their counsel. 3'
As a result of this diverse and often narrow educational and training
experience, two problems emerge. First,
because most physicians lack adequate training in diagnosing
genetic defects, misdiagnosis and inappropriate advice can
be serious problems. For example, if a couple are told
that a given problem is genetic and accordingly opt for
sterilization, they have taken an irreversible step. If
the doctor was wrong, not only has he caused the couple
much grief, but he is legally liable. The current structure
of genetic counseling facilities combined with the lack of
diagnostic capacity make such problems likely. In addition,
given the current lack of training in medical genetics,
practicing physicians probably ignore the genetic aspects
of many diseases.233
The second problem which stems from this diversity in backgrounds is that
Professional counselors . . . tend to erect fences
around their area of counseling interest and, by fiat,
allow other professionals to give genetic facts but not
counseling.
Counseling preserves established by vested areas of interest
also increase the likelihood that families will miss
vital pieces of information. When no one person carries
232 James R. Sorenson, "Factors Shaping Decision Making in Applied Human
Genetics: Professional and Client Perspectives," Department of Sociology,
Princeton University, August 1972, p. 4.
233
Sorenson, op. cit., supra, n. 169 at 27.
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the primary responsibility for organizing the genetic
information and counseling the family, important aspects
of information may be overlooked. 234
There is a need, therefore, to define qualifications and to provide
proper training for genetic counselors and to consider appropriate guidelines
for the conduct of counseling services. Ladimer suggests that appropriate
standards should cover the
(1) definition of the field or process of genetic counseling;
(2) scope of services; (3) practitioners qualified to serve;
(4) institutional and other settings suitable for counseling;
(5) protection of interests; (6) relation to other fields,
professions and services; (7) methods for evaluation; and
(8) professional and community obligations. 235
Certainly, an important goal of training counselors should be to sensitize
them to the wide variety of needs and expectations that may be expressed by
their patients.
B. Role Orientation: Sensitizing the genetic counselor to patient needs
and expectations naturally raises the question of how he should relate to his
patients. The role orientation of counselors has been a subject of considerable
discussion. Two basic positions can be distinguished. On the one hand, there
are those who view the counselor as an informer, whose task is simply to
inform the couples of the risks involved. They see any attempt on the
counselor's part to influence the decisions of those whom he counsels as beyond
his professional responsibility as a counselor. On the other hand, there are
those who view the counselor as a wise advisor, one whose concern for the
patient exceeds a mere presentation of the facts and calls for a closer
234
Reisman and Matheny, op. cit., supra, n. 15 at 27.
235
Op. cit., supra, n. 186 at 13.
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involvement with his counselees. No matter which of the two views one
adopts, it is important to recognize the influential role which a counselor
can assume. Sorenson has observed that
counselees are often informationally dependent on the
counselor for not only a technical diagnosis and assessment
of their situation, but they seek in addition some assistance
in giving meaning to the condition they find themselves in,
a condition of calculated risk, but a condition for which
there are few behavioral precedents as to how to interpret
these risks or how to make sense out of them.236
Thus, lacking adequate and meaningful information, a couple seeking help is
confused and worried. They are searching for someone with authority to
answer their questions and this "dependency role" may make them more
susceptible to the counselor's own views. And it is difficult, if not
impossible, for the feelings of the counselor not to be conveyed to his
237
patients. The opportunities which exist for counselors to influence the
decision of a couple are illustrated by the following example.
If the couple is facing the risk for an autosomal recessive
disorder the counselor can tell the couple that they have
a three in four chance of having a normal child. He might
do this if he thinks that the couple ought to have more
children. On the other hand, if he is pessimistic and
believes that the couple ought not to chance reproducing
he might say that they face a risk of one in four that the
child will be abnormal. In both cases the same factual
236. cit., supra, n. 232 at 15. Sorenson presents an excellent
description and analysis of the context in which genetic counseling occurs,
emphasizing the evolution of a new doctor-patient relationship and its
implications for applied genetic decision-making.
237Fletcher's study tends to support this point, with the finding that
"The counselor's wishes for outcomes in a case will be conveyed directly or
indirectly to the patient." (emphasis added) Op. cit., supra, n. 134 at 60.
The importance of recognizing and analyzing the nature of this influence is
stressed by Sorenson, who writes that "the ultimate role of who makes final
decisions regarding the use of genetic knowledge is usually less ethically
and morally neutral than is the situation in the delivery of more standard
medical services." Op. cit., supra, n. 196 at 19.
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information is conveyed to the clients. In the first
situation the counselor stresses normality, while in
the second he stresses the potential abnormality. This
variation is certain to have an impact on the decision
of the clients.238
Thus, the genetic counselor's own biases may well become important factors
influencing a family's decision.
C. Doctor-Patient Communication: The ultimate quality of genetic
counseling will, to a large extent, depend on the interaction between the
patient and the counselor. Of the various factors which contribute to this
interaction, certainly one of the most crucial is the communicative process
between the counselor and his counselees. How well do patients receive,
comprehend, and apply the information given to them by their physicians?
To what extent are instances of misunderstanding and distortion due to the
patient's or physician's inability to "communicate"? Answers to these
questions are crucial, for it may well be that shortcomings in the treatment
of a chronic illness can be related to such misunderstanding or distortion.239
There appear to be at least three pertinent clearly-defined variables
in the doctor-patient communicative process. First, there is the ability of
the physician-counselor to communicate information to his counselees. Of
what value is it to have pertinent information unless the counselor is able
238Sorenson, op. cit., supra, n. 196 at 22.
239Undoubtedly, many individuals distort, forget, or reject the genetic
information conveyed to them by the genetic counselor. A study of parental
understanding of phenylketonuria concludes: "If exposing parents to medical
information aims at improving their understanding of the illness or at
favorably influencing the course of the child's illness, the present study
provides no support for either contention." Maarten S. Sibinga and C. Jack
Friedman, "Complexities of Parental Understanding of Phenylketonuria,"
Pediatrics, Vol. 46, August 1971, p. 222. The study's sample population
included 42 families of children with PKU.
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to deliver it effectively? But while it is the counselor's role to promote
effective communication, it is a role,'according to some, "for which most
,,240
physicians have unfortunately had little training."240 The problem resulting
from poor communication is described by a recent study of doctor-patient
communication in a pediatric clinic of a large hospital. The study found
that physicians tend to be overly technical in the language they use with
their patients. "In more than half of the cases we recorded the physicians
resorted to medical jargon. This did not necessarily leave the patient
dissatisfied; . . . It did, however, leave most of the mothers unenlightened
241
about the nature of the child's illness." This problem is also applicable
to genetics. Unless the information is properly explained and understood, it
may evoke unreasonable fear on the part of families. For example, in a
follow-up study at a genetic counseling clinic, it was found that in some
instances odds had no meaning to couples. "The mother of a child with a
myelocele remembered that she had been given a 1 in 25 risk, but said that
if she had another child 'either it would or would not be affected and so the
risk is 50/50'."242 On the basis of her reasoning, this woman had adopted
three children. Unquestionably, then, "attention to effective communication,
a skill that should not be too difficult for any trained person to master,
could make a valuable contribution to the quality of health care and its
availability to the general population."243 Genetic counseling would appear
240
Reisman and Matheny, op. cit., supra, n. 15 at 30.
241
Barbara Korsch and Vida Megrete, "Doctor-Patient Communication,"
Scientific American, Vol. 227, August 1972, pp. 71-72.
242Carter, et. al., op. cit., supra, n. 163 at 282.
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to have much to gain from a concerted effort in this direction.
In a recent study in a congenital heart clinic with a well trained
genetic counseling unit, it was found that after receiving genetic information
only about 25 per cent of the families retained and understood the attendant
244
recurrence risks. Thus, even with highly-skilled genetic counselors, the
reception and understanding of genetic information was significantly impaired.
This leads to a second variable in the doctor-Datient communicative process:
the basic knowledge of biology and genetics that patients bring to the
counseling session. Leonard and his colleagues found that "the substratum
of biologic knowledge possessed by many parents is inadequate to support
the information imposed upon it by the counselor."245  In the long run,
therefore, there is a need for a better-educated public. Of more immediate
concern, however, is the need for systematic and empirical investigation into
how counseling information is received and applied. Perhaps such information
should be repeated. If so, how often and at what intervals? It might also be
helpful to modify counseling services to the specific educational and socio-
economic backgrounds of the consumers. How this might be most effectively
and efficiently accomplished will require additional study.
While greater education is a necessary nrerequisite for more effective
doctor-patient communication, it is apparently not always suffient for
producing the desired effect, e.g. the family's understanding of the counseling
information. In a study of PKU families, "Parents with greater education were
244
J.A. Reiss and V.D. Menashe, "Genetic Counseling and Congenital Heart
Disease," Journal of Pediatrics, 80:655-656, April 1972.
245Leonard, et. al., op. cit., supra, n. 165 at 438.
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no less inaccurate or distortion prone than those with less education
The investigators suggest that "the capability to understand illness might be
considered an emotional phenomenon."247 Thus, a third important variable is
the context in which genetic counseling is provided. A recent study of genetic
counseling cited "emotional conflict" as an inhibiting influence on a family's
understanding of counseling information. 248 To what extent, then, do parents
remember information given to them when the context is so emotionally charged?
Is reinforcement required? If so, what forms should it take? Clearly, the
emotional context of genetic counseling requires careful assessment when
considering ways to improve the counseling process.
Doctor-patient communication, then, is an essential element of the
counseling process and thus becomes an important criteria for designing and
evaluating genetic screening programs. The three variables discussed above
must be viewed as essential elements of doctor-patient communication, which,
if carefully studied, evaluated and improved upon, could contribute to more
effective control of genetic disease.
D. "Responsible" Genetic Counseling: How one defines the responsibility
of the genetic counselor to his patients will depend, to a large extent, on the
way one characterizes the practice of genetic medicine. There are those who
contend that genetic screening and counseling are altering the paradigm of the
246Sibinga and Friedman, op. cit., supra, n. 239.
24 7Ibid.
248
Leonard, et. al., op. cit., supra, n. 165. The investigators noted
(p. 435) that five of the families interviewed "observed that the genetic
information given at the time of diagnosis or shortly thereafter was not
retained because of emotional shock." Also, see supra, pp. 63-64.
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traditional doctor-patient relationship and thus changing the nature of the
physician's responsibilities within that context. Traditionally, the practice
of medicine was primarily devoted to individual therapy, with the patient
the responsibility of a single physician. Large-scale screening programs,
however, have shifted the focus of attention from the individual to a larger
population and from a single physician to team care. While medical codes
regarding the professional responsibilities of the physician to his patient
have been adequate for those problems arising from the traditional practice
of medicine, new genetic technology and the kinds of medicine it makes
possible may require a reevaluation of the ethical norms governing medicine,
Perhaps the best illustration of the problems which can arise concerns the
kinds of information that should be given to the patient.
Under the traditional doctor-patient relationship, the physician
examines his patient and, on the basis of his diagnosis, then acts to prescribe
the most effective alternative for alleviating the illness. In this
arrangement, the patient assumes that the physician possesses superior
knowledge concerning questions of medicine and health. This is not the case
in genetic counseling. "There is no assurance that a counselor has any more
expertise than the counselee in evaluating risks for recurrence of a problem
or in estimating the ability of the family to adequately handle a problem,
249
should it occur." Under these circumstances, then, the counselor gives a
couple information so that they can act, rather than as a prerequisite to his
acting on them. Questions arise, however, concerning the status of a
249Sorenson, op. cit., supra, n. 232 at 9.
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physician's therapeutic privilege in the counseling context. What information
should he give to his patients? Unfortunately, traditional ethical precepts
offer little guidance. Consequently,
Since there are few normative guidelines outlining the
information that should be given in the counseling sessions,
other than the provision of minimal information about the
disease and its recurrence risk, the actual information
that is exchanged, and the degree to which this constitutes
counsel, advice, or behavioral suggestion, varies depending
on the particular conditions.250
The problems which may emerge from this unsettled situation can be
demonstrated by the following "cases."
Earlier discussion of the XYY chromosome abnormality emphasized the
inconclusive nature of research concerning its consequences on human behavior
(supra, pp. 73-74). Assume for the moment that amniocentesis is performed on
an expectant mother concerned that her child might be a Tay-Sachs baby.
While no evidence of Tay-Sachs disease is found, the abnormal XYY chromosome
abnormality is discovered. What should the counselor tell the mother? One
question which this example raises is whether a counselor can simply act as
an "informer," responsible only for providing his patients with the facts?
In the case of the XYY anomaly, what are the "facts"? What consideration
should the counselor give to the effect on the parents and their family
situation if given this information? Might parental concern about the possible
presence of an abnormality adversely influence their care of the child? A
recent report on the XYY anomaly suggested that "parental expectations and
apprehensions about possible - but as yet unknown or even non-existant -
250Ibid., pp. 16-17.
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problems, may well create certain difficulties and lead unwittingly to
251
self-fulfilling prophecies." Perhaps more importantly, should individual
counselors, each with their own built-in biases and operating within the
context of varied family situations, be given the responsibility to make
such decisions? By whom and by what criteria should such responsibility be
allocated? And if a child or young adult, while participating in a screening
program to detect other sex anomalies is found to be an "XYY" should he be
informed of this condition? Ramsey raises the question of "whether the
individual might be endangered by the acquisition, in any society, of complete
knowledge [or in the XYY case, of partial and as yet unconfirmed knowledge]
of his behavioral genetics? Such knowledge may be too heavy for many to bear
252
and still remain spontaneous and free in their personal lives." Without
any common ethical perspective, answers to these questions would undoubtedly
vary from counselor to counselor and according to the situational context in
which they occur.
In cases in which early detection of a disease cannot be accompanied by
appropriate treatment for the patient or his family, the question arises
whether the uncovering of the disease does more harm than good. The urgency
of this question is demonstrated by the possible development of a safe and
253'
accurate test for presymptomatic detection of Huntington's chorea. A
251
Shah (ed.), op. cit., supra, n. 220 at 26.
252
252p. cit., supra, n. 86 at 174.
253 H.C. Klawans, G.W. Paulson and A. Barbeau, "Predictive Test for
Huntington's Chorea," Lancet, 2: 1185-86, December 5, 1970. The authors
report using "levodopa" as their testing agent. They stress the need, however,
for additional experimental testing and caution against hasty interpretations
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reliable and accurate test will mean that persons who lack the deleterious
gene will be reassured that the disease will not develop, and, thus, they
will also be reassured that any children that they might have will be
unaffected. But for those whose tests are positive, they will be confronted
with the fact that their future will include gradual physical and mental
degeneration. This possibility has led some to argue that "it is not
unreasonable to withhold the use of a test of this sort until we have something
tangible to offer to those who give a positive result," suggesting that
254
"depression and the risk of suicide would be more or less inevitable."
There are those who would object to this alternative, finding "no reason to
deprive the patients involved of the right of decision to learn, early or late,
their inevitable fate."255 (emphasis added) It is important to remember that
if the test is to be of value, persons with predictive signs of Huntington's
chorea must refrain from having their own children. If such persons are to
be informed, then it is imperative that the counselor carefully evaluate the
emotional state of the patient prior to telling him. "Should the diagnosis
be confirmed without proper preparation, serious behavioral or mood disorders
may ensue, including suicide." 256 Thus, what is to be told and how it is to
of test results, noting that "A positive result does not prove Huntington's
chorea, it only increases the prediction coefficient . . . A negative result
is still meaningless and requires new evaluation in years to come."
254David L. Stevens, "Test for Huntington's Chorea (cont.)," The New
England Journal of Medicine, Vol. 285, August 12, 1971, p. 414.
2 55Willard Gaylin, "Genetic Screening: The Ethics of Knowing," The New
England Journal of Medicine, Vol. 286, June 22, 1972, p. 1362.
256Whittier, et. al., op. cit., supra, n. 209 at 1550.
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be told assume new proportions in the information equation established
between the counselor and his patient.
While the above examples are single, isolated cases, they help to
demonstrate some of the issues which may emerge concerning the counselor's
responsibility in providing information to his counselees. A general overview
of this responsibility highlights four additional policy questions. First is
the question of whether persons are deprived of their freedom of choice when
pertinent information is withheld. Without the knowledge necessary for
making intelligent decisions, is the power to decide still meaningful? When
arbitrating the question of what to communicate to the patient, it should be
remembered that "For parents, genetic counseling can constitute a fundamental
crisis. or emerqency. in their reproductive careers. At issue is the decision
257
as to whether to keep open or to close the social family biologically."
To what extent, then, should a "third party" be permitted to take that decision
(in any meaningful sense of the term) away from a couple?
A second issue concerns the validity of the assumption that the withholding
of information would be in the best interests of the patient. Some geneticists
express the opinion that, in the case where there is no effective therapy for
an illness, informing the patient and his family of his condition will do more
harm than good. Knowledge of the condition
prior to its clinical manifestation may merely provoke
increased patient or parental anxiety without offering
them any positive reassurance. There will be little
benefit to the patient and, for a time, at least, some
possible degree of harm to the parents and patient,
depending upon their emotional stability.258
257Sorenson, op. cit., supra, n. 232 at 10.
258Murray, op. cit., supra, n. 189 at 10.
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It is certainly questionable, however, whether the counselor will be able
to determine what the "best interests" of his counselee are. Genetic
counselors, unlike the family physician, are not well-acquainted with their
patients and their families. Thus, some believe that "When counseling
becomes much more routine, part of the accepted practice should not be the
routine of withholding information from the counselees on the spurious
grounds that the counselors know what is best for patients they hardly know
259
at all." There is also the problem of a physician's own values, which may
differ from those of his patients, and the effect that they might have on his
judgment to discern his patient's best interests. "The potential for conflict
is especially great in genetic counseling in which the options elected depend
on one's opinions about such controversial matters as the importance of the
260
traditional concept of family, the morality of divorce and of abortion,
The cornerstone of the doctor-patient relationship is the patient's trust
in the integrity and ability of his physician. This poses a third question:
If information that is withheld today is discovered later, what will be the
effect on the relationship between the medical profession, and particularly
genetic counseling, and its patients? Might there be a general loss of
confidence in the medical profession brought about by the routine withholding
of information? When could a patient be sure that he was being told all?
The possible damage to the practice of medicine and its consequent impact on
259
Alexander M. Capron, "Ethical and Legal Aspects of Genetic Counseling,"
Paper presented at the First Advanced Symposium: Genetic Counseling, The
New England Institute, Ridgefield, Connecticut, July 6, 1972, p. 4.
2601bid., p. 5.
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the health of the population must be added to the growing list of policy
considerations.
The fourth and final broad policy question concerns the nature of the
counselor's responsibility beyond his individual patient. Specifically,
what is the responsibility of the counselor toward a patient's family and
society? With respect to access to information, it has been suggested that
"As a general rule all unambiguous diagnostic results should be made available
261
to the person, his legal representative, or a physician authorized by him."
A question arises as to whether a patient's family should also be told, since
this might give them the opportunity to evaluate intelligently their own
health status. It has been suggested that the traditional, confidential
doctor-patient relationship might be less important than people's "right to
262
know about the risks that they run, whether infectious, toxic, or genetic."
And if such information is withheld, could the physician or screening program
administrators be found legally negligent?
There may be instances in genetic medicine where the needs of the
individual and those of society conflict. Considering the possible dangers
of the presence of the XYY chromosome abnormality, does the counselor have the
responsibility to forewarn the community and perhaps expose the XYY individual
and his family to an undercurrent of social and legal pressures? And upon
making a diagnosis of Down's syndrome and advising his counselees, to what
extent should the counselor consider the costs to society of providing
261
Institute of Society, Ethics and the Life Sciences, op. cit., supra,
n. 154 at 1131.
262John Littlefield, quote in Time, June 26, 1972, p. 51.
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institutional care for that child? This issue requires considerable thought
and leads one to ask if the individual physician is in a position to measure
and evaluate the cumulative, and sometimes remote, effects of his individual
acts? Should such considerations influence the case of his patient? It
might well be that "The individual physician is unfaithful to the trust the
patient places in him if he withholds a specific therapeutic agent in
anticipation of some eventual perturbation of human ecology. Society,
263
therefore, cannot possibly delegate such decisions to each physician."
But how society and its institutions is to make these decisions is far from
clear.
Genetic technology is becoming an increasingly important part of
society's vast medical arsenal. Applying such knowledge, however, may create
a myriad of problems. In the hope of stimulating discussion and focusing
attention on the most pressing policy issues related to genetic technology,
this paper has sought to identify and analyze some of the major problem
areas. It is apparent that society must begin to make some conscious
decisions regarding the use of this technology. How these decisions are
made will affect not only the health of this generation, but that of many
generations to come. These, then, are the promises and problems of genetic
technology.
263
Edmund D. Pellegrino, "Physician, Patients, and Society: Some New
Tensions in Medical Ethics," in E. Mendelsohn, et. al., op. cit., supra,
n. 47 at 80.
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